Document:

NOTE
AND WARRANT PURCHASE AGREEMENT

    

    This
NOTE AND WARRANT PURCHASE
AGREEMENT (this “Agreement”) is made
as of the last date set forth on the signature page hereof between CORMEDIX INC., a Delaware
corporation having its principal place of business at 86 Summit Avenue, Suite
301, Summit, NJ 07901-3647 (the “Company”), and the
undersigned (the “Subscriber”).

    

    WITNESSETH:

    

    WHEREAS, the Company has
retained Paramount BioCapital, Inc. (the “Placement Agent”) to
act as its exclusive placement agent, on a “best efforts, all or none” basis, in
a private offering (the “Offering”) of
convertible promissory notes in substantially the form attached hereto as Exhibit A (the “Notes”) included in
the Minimum Offering (as defined below) and on a “best efforts” basis in the
Offering of such Notes which will provide the Company with aggregate proceeds in
excess of the Minimum Offering, and in connection therewith has authorized
Paramount to engage one or more other firms to assist in finding qualified
subscribers for the Notes (such other firms, if any, together with Paramount,
the “Placement
Agent”);

    

    WHEREAS, the terms of the
Offering are summarized in that certain Confidential Offering Memorandum dated
June 15, 2007 (together with all amendments, supplements, exhibits and
appendices thereto, the “Memorandum”);

    

    WHEREAS, the Company desires
to offer and sell a minimum of $500,000 aggregate principal amount of Notes (the
“Minimum
Offering”) and a maximum of $10,000,000 aggregate principal amount of
Notes (the “Maximum
Offering”), with an option in favor of the Placement Agent and the
Company to offer up to an additional $2,000,000 aggregate principal amount of
Notes (the “Over-allotment,” and
together with the Maximum Offering, the “Maximum Amount”)
(such amount of Notes actually issued, the “Principal Loan
Amount”).  In addition to the Notes, each Subscriber will
receive a seven-year warrant (the “Warrant”), in
substantially the form attached hereto as Exhibit B, to
purchase a number of shares of common stock, $0.001 par value per share (the
“Common
Stock”), of the Company equal to (i) 25% of the principal amount of the
Notes purchased by it divided by the lowest price per share in an equity
financing or series of related equity financings by the Company resulting in
aggregate gross cash proceeds (before commissions or other expenses and
excluding conversion of the Notes) to the Company of at least $10,000,000 minus
the aggregate principal amount of the Second Bridge Notes (as defined herein) (a
“Qualified
Financing”) at which equity securities of the Company are sold (the
“Lowest Price
Paid”), if a Qualified Financing is consummated within one hundred eighty
(180) days after the Initial Closing (as defined below) of this Offering (the
“Qualified Financing
Date”), or (ii) 40% of the principal amount of the Notes purchased by it
divided by the Lowest Price Paid, if a Qualified Financing is not consummated on
or before the Qualified Financing Date, in each case, at a per Warrant exercise
price equal to 110% of the Lowest Price Paid.  Notwithstanding the
foregoing, if a Qualified Financing does not occur on or before the second
anniversary of the Initial Closing, then each Warrant will be exercisable for
that number of shares of Common Stock equal to forty percent (40%) of the
principal amount of the Note purchased by the original holder divided by $1.00,
at a per share exercise price of $1.00.  Notwithstanding the
foregoing, upon a Sale of the Company (as defined in the Notes) or a Reverse
Merger (as defined in the Notes), the Notes and Warrants shall be subject to
certain terms and conditions, in each case as defined and described in detail in
the Notes and Warrants.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    WHEREAS, the Company desires
to enter into this Agreement to issue and sell the Notes and the Subscriber
desires to purchase the principal amount of Notes set forth on the signature
page hereto on the terms and conditions set forth herein; and

    

    NOW, THEREFORE, in
consideration of the promises and the mutual representations and covenants
hereinafter set forth, the parties hereto do hereby agree as
follows:

    

    I.           SUBSCRIPTION FOR NOTES AND
REPRESENTATIONS BY SUBSCRIBER

    

    1.1           Subject
to the terms and conditions hereinafter set forth, the Subscriber hereby
irrevocably subscribes for and agrees to purchase from the Company that portion
of the aggregate principal amount of the Principal Loan Amount authorized to be
issued by the Company set forth on the signature page hereto (the “Subscriber Loan
Amount”).  The purchase price is payable by wire transfer of
immediately available funds to:

    

    
      
        	
                Bank:

              	
                U.S.
      Bank Trust N.A.

              
	
                ABA
      Number:

              	
                091000022

              
	
                Further
      Credit to Account Name:

              	
                U.S.
      Bank and Trust Corp Trust Acct

              
	
                Account
      #:

              	
                180121167365

              
	
                Final
      Beneficiary Recipient/Subacct:

              	
                Paramount
      BioCapital & CorMedix

              
	
                SEI/Subacct
      Number:

              	
                113203000

              
	
                Reference:

              	
                [Investor
      Name]

              
	
                Attention:

              	
                Andrea
      Friesen

              
	 
      	
                651-495-3725
      (phone)

              
	 
      	
                651-495-8087
      (fax)

              

      

    

    

    Upon
acceptance by the Placement Agent and the Company of subscriptions for an amount
of Notes equal to at least the Minimum Offering, the Placement Agent and the
Company shall have the right at any time thereafter, prior to the Offering
Termination Date (as defined in Section 3.2), to effect an initial closing with
respect to the Offering (the “Initial
Closing”).  Thereafter, the Placement Agent and the Company
shall continue to accept additional subscriptions for, and continue to have
closings (together with the Initial Closing, each a “Closing” and the date
thereof the “Closing
Date”) with respect to subscriptions for Securities (as defined below)
from new or existing investors from time to time and at any time up to the
Offering Termination Date.

    

    The
Subscriber understands that the Company’s and the Placement Agent’s respective
officers, directors, employees and/or affiliates may purchase Notes in this
Offering, which purchases may be used to satisfy the Minimum
Offering.  In addition, certain employees of the Placement Agent and
its affiliates are current stockholders of the Company.

    
      
         

      

      
        2

        
          

        

      

      
         

      

    

    

    1.2           The
Subscriber recognizes that the purchase of the Notes involves a high degree of
risk including, but not limited to, the following: (a) the Company remains a
development stage business with limited operating history and requires
substantial funds in addition to the proceeds of the Offering; (b) an investment
in the Company is highly speculative, and only investors who can afford the loss
of their entire investment should consider investing in the Company and the
Notes; (c) the Subscriber may not be able to liquidate its investment; (d)
transferability of the Notes and the securities issuable upon conversion of the
Notes and the Common Stock underlying the Warrant (sometimes hereinafter
collectively referred to as the “Securities”) is
extremely limited; (e) in the event of a disposition of the Securities, the
Subscriber could sustain the loss of its entire investment; and (f) the Company
has not paid any dividends on its capital stock since its inception and does not
anticipate paying any dividends in the foreseeable future.  Without
limiting the generality of the representations set forth in Section 1.5 below,
the Subscriber represents that the Subscriber has carefully reviewed the section
of the Memorandum captioned “Risk Factors.”

    

    1.3           The
Subscriber represents that the Subscriber is an “accredited investor” as such
term is defined in Rule 501 of Regulation D (“Regulation D”)
promulgated under the Securities Act of 1933, as amended (the “Securities Act”), as
indicated by the Subscriber’s responses to the questions contained in Article
VII hereof, and that the Subscriber is able to bear the economic risk of an
investment in the Securities.  If the Subscriber is a natural person,
the Subscriber has reached the age of majority in the state or other
jurisdiction in which the Subscriber resides, has adequate means of providing
the for the Subscriber’s current financial needs and contingencies, is able to
bear the substantial economic risks of an investment in the Securities for an
indefinite period of time, has no need for liquidity in such investment and, at
the present time, could afford a complete loss of such investment.

    

    1.4           The
Subscriber hereby acknowledges and represents that (a) the Subscriber has
sufficient knowledge and experience in business and financial matters, prior
investment experience, including investment in securities that are non-listed,
unregistered and/or not traded on a national securities exchange, or the
Subscriber has employed the services of a “purchaser representative” (as defined
in Rule 501 of Regulation D), attorney and/or accountant to read all of the
documents furnished or made available by the Company both to the Subscriber and
to all other prospective investors in the Securities in order to evaluate the
merits and risks of such an investment on the Subscriber’s behalf; (b) the
Subscriber recognizes the highly speculative nature of this investment; and (c)
the Subscriber is able to bear the economic risk that the Subscriber hereby
assumes.

    

    1.5           The
Subscriber hereby acknowledges receipt and careful review of this Agreement, the
Note, the Warrant and the Memorandum (which includes the Risk Factors),
including all exhibits thereto (collectively referred to as the “Offering Materials”)
and hereby represents that the Subscriber has been furnished by the Company
during the course of the Offering with all information regarding the Company,
the terms and conditions of the Offering and any additional information that the
Subscriber, its purchaser representative, attorney and/or accountant has
requested or desired to know, and has been afforded the opportunity to ask
questions of and receive answers from duly authorized officers or other
representatives of the Company concerning the Company and the terms and
conditions of the Offering.

    
      
         

      

      
        3

        
          

        

      

      
         

      

    

    

    1.6           (a)           In
making the decision to invest in the Securities, the Subscriber has relied
solely upon the information provided by the Company in the Offering
Materials.  To the extent necessary, the Subscriber has retained, at
its own expense, and relied upon appropriate professional advice regarding the
investment, tax and legal merits and consequences of this Agreement and the
purchase of the Securities hereunder.  The Subscriber disclaims
reliance on any statements made or information provided by any person or entity
in the course of Subscriber’s consideration of an investment in the Securities
other than the Offering Materials.  The Subscriber acknowledges and
agrees that (i) the Company has prepared the Offering Materials and that no
other person, including without limitation, the Placement Agent, has supplied
any information for inclusion in the Offering Materials other than information
furnished in writing to the Company by the Placement Agent specifically for
inclusion in those parts of the Offering Materials relating specifically to the
Placement Agent, (ii) the Placement Agent has no responsibility for the accuracy
or completeness of the Offering Materials and (iii) the Subscriber has not
relied upon the independent investigation or verification, if any, that may have
been undertaken by the Placement Agent.

    

    (b)           The
Subscriber represents that (i) the Subscriber was contacted regarding the sale
of the Securities by the Company or the Placement Agent (or an authorized agent
or representative of the Company or the Placement Agent) with whom the
Subscriber had a prior substantial pre-existing relationship and (ii) no
Securities were offered or sold to it by means of any form of general
solicitation or general advertising, and in connection therewith, the Subscriber
did not (A) receive or review any advertisement, article, notice or other
communication published in a newspaper or magazine or similar media or broadcast
over television or radio, whether closed circuit, or generally available; or (B)
attend any seminar meeting or industry investor conference whose attendees were
invited by any general solicitation or general advertising.

    

    1.7           The
Subscriber hereby represents that the Subscriber, either by reason of the
Subscriber’s business or financial experience or the business or financial
experience of the Subscriber’s professional advisors (who are unaffiliated with
and not compensated by the Company or any affiliate or selling agent of the
Company, including the Placement Agent, directly or indirectly), has the
capacity to protect the Subscriber’s own interests in connection with the
transaction contemplated hereby.

    

    1.8           The
Subscriber hereby acknowledges that the Offering has not been reviewed by the
United States Securities and Exchange Commission (the “SEC”) nor any state
regulatory authority since the Offering is intended to be exempt from the
registration requirements of Section 5 of the Securities Act pursuant to
Regulation D promulgated thereunder.  The Subscriber understands that
the Securities have not been registered under the Securities Act or under any
state securities or “blue sky” laws and agrees not to sell, pledge, assign or
otherwise transfer or dispose of the Securities unless they are registered under
the Securities Act and under any applicable state securities or “blue sky” laws
or unless an exemption from such registration is available.

    
      
         

      

      
        4

        
          

        

      

      
         

      

    

    

    1.9           The
Subscriber understands that the Securities have not been registered under the
Securities Act or any state securities laws by reason of a claimed exemption
under the provisions of the Securities Act and such state securities laws that
depends, in part, upon the Subscriber’s investment intention. The Subscriber
hereby represents that the Subscriber is purchasing the Securities for the
Subscriber’s own account for investment and not with a view toward the resale or
distribution to others.  The Subscriber, if an entity, further
represents that it was not formed for the purpose of purchasing the
Securities.

    

    1.10         The
Subscriber understands that there is no public market for the Securities and
that no market may develop for any of such Securities.  The Subscriber
understands that even if a public market develops for such Securities, Rule 144
(“Rule 144”)
promulgated under the Securities Act requires for non-affiliates, among other
conditions, a one-year holding period prior to the resale (in limited amounts)
of securities acquired in a non-public offering without having to satisfy the
registration requirements under the Securities Act.  The Subscriber
understands and hereby acknowledges that the Company is under no obligation to
register any of the Securities under the Securities Act or any state securities
or “blue sky” laws other than as set forth in Article V.

    

    1.11         The
Subscriber consents to the placement of a legend on any certificate or other
document evidencing the Securities that such Securities have not been registered
under the Securities Act or any state securities or “blue sky” laws and setting
forth or referring to the restrictions on transferability and sale thereof
contained in this Agreement.  The Subscriber is aware that the Company
will make a notation in its appropriate records with respect to the restrictions
on the transferability of such Securities. The legend to be placed on each
certificate shall be in form substantially similar to the
following:

    

    “THE
SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES
SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”) OR ANY STATE SECURITIES OR “BLUE
SKY LAWS”, AND MAY NOT BE OFFERED, SOLD, TRANSFERRED, ASSIGNED, PLEDGED OR
HYPOTHECATED ABSENT AN EFFECTIVE REGISTRATION THEREOF UNDER SUCH ACT, OR UNLESS
THE COMPANY HAS RECEIVED AN OPINION OF COUNSEL, REASONABLY SATISFACTORY TO THE
COMPANY AND ITS COUNSEL, THAT SUCH REGISTRATION IS NOT REQUIRED.”

    

    1.12          The
Subscriber hereby represents that the address of the Subscriber furnished by
Subscriber on the signature page hereof is the Subscriber’s principal residence
if Subscriber is an individual or its principal business address if it is a
corporation or other entity.

    

    1.13         The
Subscriber represents that the Subscriber has full power and authority
(corporate, statutory and otherwise) to execute and deliver this Agreement and
to purchase the Securities.  This Agreement constitutes the legal,
valid and binding obligation of the Subscriber, enforceable against the
Subscriber in accordance with its terms.

    
      
         

      

      
        5

        
          

        

      

      
         

      

    

    

    1.14           If
the Subscriber is a corporation, partnership, limited liability company, trust,
employee benefit plan, individual retirement account, Keogh Plan, or other
tax-exempt entity, (a) it is authorized and qualified to invest in the Company
and the person signing this Agreement on behalf of such entity has been duly
authorized by such entity to do so and (b) it is duly organized, validly
existing and in good standing under the laws of the jurisdiction of its
organization.

    

    1.15           The
Subscriber acknowledges that if he or she is a Registered Representative of a
National Association of Securities Dealers, Inc. (the “NASD”) member firm,
he or she must give such firm the notice required by NASD Rule 3050, receipt of
which must be acknowledged by such firm in Section 7.4 below.

    

    1.16           Subject
to the provision below, the Subscriber hereby agrees that in the case of an
initial offering of the Common Stock to the public pursuant to an effective
registration statement under the Securities Act (the “IPO”), the Subscriber
will not, without the prior written consent of the Company, offer, pledge, sell,
contract to sell, grant any option for the sale of, or otherwise dispose of,
directly or indirectly, the Registrable Securities (as defined in Section 5.1)
purchased or acquired by the Subscriber for a period of up to 180 days from the
effective date of the registration statement relating to the IPO and that the
Subscriber will enter into an agreement with the Company or managing underwriter
of the IPO to that effect.

    

    1.17  
       (a)           The
Subscriber agrees not to issue any public statement with respect to the
Subscriber’s investment or proposed investment in the Company or the terms of
any agreement or covenant between them and the Company without the Company’s
prior written consent, except such disclosures as may be required under
applicable law or under any applicable order, rule or regulation.

    

     (b)           The
Company agrees not to disclose the names, addresses or any other information
about the Subscribers, except as required by law; provided, that the Company may
use the name (but not the address) of the Subscriber in any registration
statement filed pursuant to Article V in which the Subscriber’s shares are
included and in any subsequent offering memorandum if the Subscriber
beneficially owns five percent (5%) or more of the Company’s voting capital
stock, on a fully-diluted or other basis, or otherwise as required by
law.

    

    1.18         The
Subscriber represents and warrants that it has not engaged, consented to or
authorized any broker, finder or intermediary to act on its behalf, directly or
indirectly, as a broker, finder or intermediary in connection with the
transactions contemplated by this Agreement.  The Subscriber hereby
agrees to indemnify and hold harmless the Company from and against all fees,
commissions or other payments owing to any such person or firm acting on behalf
of such Subscriber hereunder.

    
      
         

      

      
        6

        
          

        

      

      
         

      

    

    1.19         The
Subscriber agrees to hold the Company and its directors, officers, employees,
affiliates, controlling persons and agents (including the Placement Agent and
its officers, directors, employees, counsel, controlling persons and agents) and
their respective heirs, representatives, successors and assigns harmless and to
indemnify them against all liabilities, costs and expenses incurred by them as a
result of (a) any sale or distribution of the Securities by the Subscriber in
violation of the Securities Act or any applicable state or foreign securities or
“blue sky” laws; or (b) any false representation or warranty or any breach or
failure by the Subscriber to comply with any covenant made by the Subscriber in
this Agreement (including the Confidential Investor Questionnaire contained in
Article VII herein) or any other document furnished by the Subscriber to any of
the foregoing in connection with this transaction; provided, however, that in no
event shall any indemnity under this subsection 1.19 exceed the aggregate
principal amount of Notes subscribed for by the Subscriber pursuant to this
Agreement, except in the case of willful fraud by the Subscriber.

    

    1.20         The
Subscriber understands, acknowledges and agrees with the Company that this
subscription may be rejected, in whole or in part, by the Company, in the sole
and absolute discretion of the Company, at any time before the Closing Date
notwithstanding prior receipt by the Subscriber of notice of acceptance of the
Subscriber’s subscription.

    

    1.21         The
Subscriber acknowledges that the information contained in the Offering Materials
or otherwise made available to the Subscriber is confidential and non-public and
agrees that all such information shall be kept in confidence by the Subscriber
and neither used by the Subscriber for the Subscriber’s personal benefit (other
than in connection with this subscription) nor disclosed to any third party for
any reason, notwithstanding that a Subscriber’s subscription may not be accepted
by the Company; provided, however, that (a) the Subscriber may disclose such
information to its affiliates and advisors who may have a need for such
information in connection with providing advice to the Subscriber with respect
to its investment in the Company so long as such affiliates and advisors have an
obligation of confidentiality, and (b) this obligation shall not apply to any
such information that (i) is part of the public knowledge or literature and
readily accessible at the date hereof, (ii) becomes part of the public knowledge
or literature and readily accessible by publication (except as a result of a
breach of this provision) or (iii) is received from third parties without an
obligation of confidentiality (except third parties who disclose such
information in violation of any confidentiality agreements or obligations,
including, without limitation, any subscription or other similar agreement
entered into with the Company).

    

    1.22         The
Subscriber represents that no authorization, approval, consent or license of any
person is required to be obtained for the purchase of the Securities by the
Subscriber, other than as have been obtained and are in full force and
effect.

    

    1.23         The
Subscriber represents that the representations, warranties and agreements of the
Subscriber contained herein and in any other writing delivered in connection
with the transactions contemplated hereby shall be true and correct in all
respects on the date hereof and as of the Closing Date on which the Subscriber
purchases Notes as if made on and as of such date and shall survive the
execution and delivery of this Agreement and the purchase of the
Notes.  The Subscriber agrees that the Company and the Placement Agent
shall be entitled to rely on the representations, warranties and agreements of
the Subscriber contained herein.

    
      
         

      

      
        7

        
          

        

      

      
         

      

    

    1.24         The
Subscriber understands, acknowledges and agrees with the Company that, except as
otherwise set forth herein, the subscription hereunder is irrevocable by the
Subscriber, that, except as required by law, the Subscriber is not entitled to
cancel, terminate or revoke this Agreement or any agreements of the Subscriber
hereunder and that this Agreement and such other agreements shall survive the
death or disability of the Subscriber and shall be binding upon and inure to the
benefit of the parties and their heirs, executors, administrators, successors,
legal representatives and permitted assigns.  If the Subscriber is
more than one person, the obligations of the Subscriber hereunder shall be joint
and several and the agreements, representations, warranties and acknowledgments
herein contained shall be deemed to be made by and be binding upon each such
person and his/her heirs, executors, administrators, successors, legal
representatives and permitted assigns.

    

    1.25         The
Subscriber understands, acknowledges and agrees with the Company that the
Offering is intended to be exempt from the registration under the Securities Act
by virtue of the provisions of Regulation D thereunder, which is in part
dependent upon the truth, completeness and accuracy of the statements made by
the Subscriber.

    

    
      	
              II.

            	
              REPRESENTATIONS BY AND
      COVENANTS OF THE COMPANY

            

    

    

    The Company hereby represents and
warrants to the Subscriber that:

    

    2.1           Organization, Good Standing
and Qualification.  The Company is a corporation duly
organized, validly existing and in good standing under the laws of the State of
Delaware and has full corporate power and authority to conduct its business as
currently conducted. The Company is duly qualified as a foreign corporation to
do business and is in good standing in every jurisdiction in which the property
owned or leased by it or the nature of the business conducted by it makes such
qualification necessary, except to the extent that the failure to be so
qualified or in good standing would not reasonably be expected to have,
individually or in the aggregate, a material adverse effect on the business,
operations, conditions (financial or otherwise), properties, assets or results
of operations of the Company (a “Material Adverse
Effect”).  The Company does not have any
subsidiaries.

    

    2.2           Capitalization and Voting
Rights.  The authorized, issued and outstanding capital stock
of the Company is as set forth in the Memorandum and all issued and
outstanding shares of the Company are validly issued, fully paid and
nonassessable.  Except as set forth in the Memorandum, there are no
outstanding options, warrants, agreements, convertible securities, preemptive
rights or other rights to subscribe for or to purchase any shares of capital
stock of the Company.  Except as set forth in the Offering
Materials and as
otherwise required by law, there are no restrictions upon the voting or transfer
of any of the shares of capital stock of the Company pursuant to the Company’s
Certificate of Incorporation, as amended (the “Certificate of
Incorporation”), By-Laws or other governing documents or any agreement or
other instruments to which the Company is a party or by which the Company is
bound.

    
      
         

      

      
        8

        
          

        

      

      
         

      

    

    2.3           Authorization;
Enforceability. The Company has all corporate right, power and authority
to enter into this Agreement and to consummate the transactions contemplated
hereby.  All corporate action on the part of the Company, its
directors and stockholders necessary for the (i) authorization, execution,
delivery and performance of this Agreement by the Company; and (ii)
authorization, sale, issuance and delivery of the Securities contemplated hereby
and the performance of the Company’s obligations hereunder has been
taken.  This Agreement has been duly executed and delivered by the
Company and constitutes a legal, valid and binding obligation of the Company,
enforceable against the Company in accordance with its terms, subject to laws of
general application relating to bankruptcy, insolvency and the relief of debtors
and rules of law governing specific performance, injunctive relief or other
equitable remedies, and to limitations of public policy.  The Notes,
when issued and fully paid for in accordance with the terms of this Agreement,
will be validly issued. Upon the issuance and delivery of the equity securities
issuable upon conversion of the Notes in accordance with the terms thereof, such
equity securities will be validly issued, fully paid and
nonassessable.  The Common Stock issuable upon exercise of the
Warrants, when issued in accordance with the terms of such Warrants, will be
validly issued, full paid and non-assessable.  The issuance and sale
of the Securities contemplated hereby will not give rise to any preemptive
rights or rights of first refusal on behalf of any person which have not been
waived in connection with this Offering.

    

    2.4           No Conflict; Governmental
Consents.

    

    (a)           Except
as would not reasonably be expected to have a Material Adverse Effect or have
been waived, the execution and delivery by the Company of this Agreement and the
consummation of the transactions contemplated hereby will not result in the
violation of any law, statute, rule, regulation, order, writ, injunction,
judgment or decree of any court or governmental authority to or by which the
Company is bound, or of any provision of the Certificate of Incorporation or
By-Laws of the Company, and will not conflict with, or result in a breach or
violation of, any of the terms or provisions of, or constitute (with due notice
or lapse of time or both) a default under, any lease, loan agreement, mortgage,
security agreement, trust indenture or other agreement or instrument to which
the Company is a party or by which it is bound or to which any of its properties
or assets is subject, nor result in the creation or imposition of any lien upon
any of the properties or assets of the Company.

    

    (b)           No
consent, approval, authorization or other order of any governmental authority or
other third party is required to be obtained by the Company in connection with
the authorization, execution and delivery of this Agreement or with the
authorization, issue and sale of the Securities, except as have been obtained or
such filings as may be required to be made with the SEC and with any state or
foreign blue sky or securities regulatory authority relating to an exemption
from registration thereunder.

    

    2.5           Licenses. Except as
would not reasonably be expected to have a Material Adverse Effect, the Company
has sufficient licenses, permits and other governmental authorizations currently
required for the conduct of its business or ownership of properties and is in
all material respects complying therewith.

    

    2.6           Litigation.  The
Company knows of no pending or threatened legal or governmental proceedings
against the Company which (i) adversely questions the validity of this Agreement
or any agreements related to the transactions contemplated hereby or the right
of the Company to enter into any of such agreements, or to consummate the
transactions contemplated hereby or thereby or (ii) could, if there were an
unfavorable decision, have a Material Adverse Effect. There is no action, suit,
proceeding or investigation by the Company currently pending in any court or
before any arbitrator or that the Company intends to initiate.

    
      
         

      

      
        9

        
          

        

      

      
         

      

    

    

    2.7           Investment
Company  The Company is not an “investment company” within the
meaning of such term under the Investment Company Act of 1940, as amended, and
the rules and regulations of the SEC thereunder.

    

    2.8           Placement
Agent.  The Company has engaged, consented to and authorized
the Placement Agent to act as agent of the Company in connection with the
transactions contemplated by this Agreement.  The Company will pay the
Placement Agent a commission in the form of both cash and warrants (the “Placement Warrants”)
and will reimburse the Placement Agent’s reasonable out-of-pocket expenses
incurred in connection with the Offering up to $100,000, and the Company agrees
to indemnify and hold harmless the Subscribers from and against all fees,
commissions or other payments owing by the Company to the Placement Agent or any
other person or firm acting on behalf of the Company hereunder.

    

    2.9           Financial Statements.
The financial statements of the Company included in Appendix D to the Memorandum
(the “Financial
Statements”) fairly present in all material respects the financial
condition and position of the Company at the dates and for the periods
indicated; and have been prepared in conformity with generally accepted
accounting principles in the United States (“GAAP”) consistently
applied throughout the periods covered thereby, except as may be otherwise
specified in such Financial Statements or the notes thereto and except that
unaudited financial statements may not contain all footnotes required by GAAP,
and fairly present in all material respects the financial position of the
Company as of and for the dates thereof and the results of operations and cash
flows for the periods then ended, subject, in the case of unaudited statements,
to normal, immaterial, year-end audit adjustments.  Since the date of
the most recent balance sheet included as part of the Financial Statements,
there has not been to the Company’s knowledge: (i) any change in the assets,
liabilities, financial condition or operations of the
Company from that reflected in the Financial Statements, other than changes in
the ordinary course of business, none of which individually or in the aggregate
would reasonably be expected to have a Material Adverse Effect; or (ii) any
other event or condition of any character that, either individually or
cumulatively, would reasonably be expected to have a Material Adverse Effect,
except for the expenses incurred in connection with the transactions
contemplated by this Agreement.

    

    2.10           Title to Properties and
Assets; Liens, Etc. The Company has good and marketable title to its
properties and assets, including the properties and assets reflected in the most
recent balance sheet included in the Financial Statements, and good title to its
leasehold estates, in each case subject to no mortgage, pledge, lien, lease,
encumbrance or charge, other than (a) those resulting from taxes which have not
yet become delinquent; (b) liens and encumbrances which do not materially
detract from the value of the property subject thereto or materially impair the
operations of the Company; (c) those that have otherwise arisen in the ordinary
course of business; and (d) those that would not reasonably be expected to have
a Material Adverse Effect.  The Company is in compliance with all
material terms of each lease to which it is a party or is otherwise
bound.

    
      
         

      

      
        10

        
          

        

      

      
         

      

    

    

    2.11         Patents and
Trademarks.  Except as would not reasonably be expected to have
a Material Adverse Effect or as disclosed in the Memorandum, to the Company’s
knowledge, (i) the Company owns or possesses adequate licenses or other rights
to use all patents, patent applications, trademarks, trademark applications,
service marks, service mark applications, trade names, copyrights, manufacturing
processes, formulae, trade secrets, licenses, customer lists and know how
(collectively, “Intellectual
Property”) , (ii) the Company has not received any communications
alleging that the Company has violated or, by conducting its business as
conducted, would violate any of the patents, trademarks, service marks, trade
names, copyrights or trade secrets or other proprietary rights or processes of
any other person or entity, nor is the Company aware of any basis therefore and
(iii) no claim is pending or, to the Company’s knowledge after due inquiry,
threatened to the effect that any Intellectual Property owned or licensed by the
Company, or which the Company otherwise has the right to use, is invalid or
unenforceable by the Company.

    

    2.12         Obligations to Related
Parties. Except as disclosed in the Memorandum or as would not reasonably
be expected to have a Material Adverse Effect, there are no obligations of the
Company to officers, directors, stockholders, or employees of the Company other
than (a) for payment of salary or other compensation for services rendered, (b)
reimbursement for reasonable expenses incurred on behalf of the Company, (c)
standard indemnification provisions in the certificate of incorporation and
by-laws, and (d) for other standard employee benefits made generally available
to all employees (including stock option agreements outstanding under any stock
option plan approved by the Board of Directors of the
Company).  Except as may be disclosed in the Financial Statements, the
Company is not a guarantor or indemnitor of any indebtedness of any other
person, firm or corporation.

    

    2.13         Employee Relations; Employee
Benefit Plans. The Company is not a party to any collective bargaining
agreement or a union contract.  The Company believes that its
relations with its employees are good.  No executive officer (as
defined in Rule 501(f) of the Securities Act) of the Company has notified the
Company that such officer intends to leave the Company or otherwise terminate
such officer’s employment with the Company.  The Company is in
compliance with all federal, state, local and foreign laws and regulations
respecting employment and employment practices, terms and conditions of
employment and wages and hours, except where failure to be in compliance would
not, either individually or in the aggregate, reasonably be expected to result
in a Material Adverse Effect.  Except as disclosed in the Memorandum,
the Company does not maintain any compensation or benefit plan, agreement,
arrangement or commitment (including, but not limited to, “employee benefit
plans”, as defined in Section 3(3) of the Employee Retirement Income Security
Act of 1974, as amended (“ERISA”)) for any
present or former employees, officers or directors of the Company or with
respect to which the Company has liability or makes or has an obligation to make
contributions, other than any such plans, agreements, arrangements or
commitments made generally available to the Company’s
employees.

    
      
         

      

      
        11

        
          

        

      

      
         

      

    

    2.14         Environmental
Laws.  To the best of its knowledge, the Company (i) is in
compliance with any and all Environmental Laws (as hereinafter defined), (ii)
has received all permits, licenses or other approvals required of it under
applicable Environmental Laws to conduct its business and (iii) is in compliance
with all terms and conditions of any such permit, license or approval where, in
each of the foregoing clauses (i), (ii) and (iii), the failure to so comply
would reasonably be expected to have, individually or in the aggregate, a
Material Adverse Effect.  The term “Environmental Laws” means all
federal, state, local or foreign laws relating to pollution or protection of
human health or the environment (including, without limitation, ambient air,
surface water, groundwater, land surface or subsurface strata), including,
without limitation, laws relating to emissions, discharges, releases or
threatened releases of chemicals, pollutants, contaminants, or toxic or
hazardous substances or wastes (collectively, “Hazardous Materials”)
into the environment, or otherwise relating to the manufacture, processing,
distribution, use, treatment, storage, disposal, transport or handling of
Hazardous Materials, as well as all authorizations, codes, decrees, demands or
demand letters, injunctions, judgments, licenses, notices or notice letters,
orders, permits, plans or regulations issued, entered, promulgated or approved
thereunder.

    

    2.15         Tax
Status.  To the best of the Company’s knowledge, the Company
(i) has made or filed all federal and state income and all other tax returns,
reports and declarations required by any jurisdiction to which it is subject,
(ii) has paid all taxes and other governmental assessments and charges that are
material in amount, shown or determined to be due on such returns, reports and
declarations, except those being contested in good faith and (iii) has set aside
on its books provision reasonably adequate for the payment of all taxes for
periods subsequent to the periods to which such returns, reports or declarations
apply.  There are no unpaid taxes in any material amount claimed to be
due by the taxing authority of any jurisdiction, and the officers of the Company
know of no basis for any such claim.

    

    2.16         Absence of Certain
Changes.  Since the date of the Memorandum, there has been no
change in the business, operations, conditions (financial or otherwise),
prospects, assets or results of operations of the Company or any of its
Subsidiaries that could reasonably be expected to have a Material Adverse
Effect.

     

    2.17         Ranking of Notes; Issuance
of New Debt.  On the Closing Date, the Notes will rank pari
passu with all of the Company’s existing indebtedness.  Following the
Closing Date, as long as any Note remains outstanding, the Company will not,
without the prior written consent of the holders of Notes evidencing at least
sixty-six and two-thirds percent (66 2⁄3%) of the Principal Loan Amount then
outstanding, incur indebtedness for borrowed money (“New Debt”) in favor of any
person or entity (each a “New Lender”) which indebtedness is secured or
otherwise senior in priority to any Note issued to any subscriber pursuant to
this Agreement or any substantially similar agreement.  No consent of
the holders of Notes will be required for issuances by the Company of unsecured
indebtedness that ranks pari passu with, or junior to, the Notes.  For purposes of this
Section 2.17 only, the term “Notes” shall include the Notes, the Second Bridge
Notes and the Galenica Note together and the term “Principal Loan Amount” shall
include the aggregate principal amount of the Notes, the Second Bridge Notes and
the Galenica Note.

     

    2.18         Disclosure.  The
information set forth in the Offering Materials as of the date hereof contains
no untrue statement of a material fact nor omits to state a material fact
necessary in order to make the statements contained therein, in light of the
circumstances under which they were made, not misleading.

    
      
         

      

      
        12

        
          

        

      

      
         

      

    

    

    III.           TERMS OF
SUBSCRIPTION

    

    3.1           The
minimum purchase that may be made by any prospective investor shall be $50,000
aggregate principal amount of Notes.  Subscriptions for investment
below the minimum investment may be accepted at the discretion of the Placement
Agent and the Company.  The Company and the Placement Agent reserve
the right to reject any subscription made hereby, in whole or in part, in their
sole discretion.  The Company’s agreement with each Subscriber is a
separate agreement and the sale of the Securities to each Subscriber is a
separate sale.

    

    3.2           Pending
the sale of the Securities, all funds paid hereunder shall be deposited by the
Company in escrow with US Bank Trust NA, having a branch at 100 Wall Street,
Suite 1600, New York, New York 10005.  This Offering will terminate on
the earlier of (i) the Company’s acceptance of subscriptions for the Maximum
Amount, or (ii) July 31, 2007, unless terminated at an earlier time or extended
by the mutual agreement of the Placement Agent and the Company without notice to
prospective investors for up to an additional sixty (60) days(the “Offering Termination
Date”).  The Company reserves the right to withdraw or cancel
this Offering and to accept or reject any subscription in whole or in part, in
its sole discretion.  The Subscriber hereby authorizes and directs the
Company and the Placement Agent to direct the Escrow Agent to return any funds
for unaccepted subscriptions to the same account from which the funds were
drawn, without interest, including any customer account maintained with the
Placement Agent.

    

    3.3           At
any time after the Company has received subscriptions and related funds for the
Minimum Offering, but prior to the Offering Termination Date, the Company may
conduct a Closing and may conduct subsequent Closings on an interim basis until
the Maximum Amount has been obtained or until the Offering Termination
Date.  Each Closing shall occur at the offices of the Placement Agent
at 787 Seventh Avenue, 48th Floor,
New York, NY 10019.

    

    3.4           The
Note and Warrant purchased by the Subscriber pursuant to this Agreement will be
prepared for delivery to the Subscriber promptly following the Closing at which
such purchase takes place. The Subscriber hereby authorizes and directs the
Company to deliver the Note and Warrant purchased by the Subscriber pursuant to
this Agreement directly to the Subscriber’s account maintained by the Placement
Agent, if any, or, if no such account exists, to the residential or business
address indicated on the signature page hereto.

    

    IV.           CONDITIONS TO OBLIGATIONS OF
THE PARTIES

    

    4.1           In
addition to the Company’s right to reject, in whole or in part, any subscription
at any time before the Closing Date, the Company’s obligation to issue the
Securities at each Closing to the applicable Subscriber is subject to the
fulfillment on or prior to such Closing of the following conditions, which
conditions may be waived at the option of the Company to the extent permitted by
law:

    
      
         

      

      
        13

        
          

        

      

      
         

      

    

    

    (a)           Representations and
Warranties Correct.  The representations and warranties made by
each Subscriber in Article I hereof shall be true and correct in all material
respects.

    

    (b)           Covenants.  All
covenants, agreements and conditions contained in this Agreement to be performed
by such Subscriber on or prior to the date of such Closing shall have been
performed or complied with in all material respects.

    

    (c)           No Legal Order
Pending.  There shall not then be in effect any legal or other
order enjoining or restraining the transactions contemplated by this
Agreement.

    

    (d)           No Law Prohibiting or
Restricting Such Sale.  There shall not be in effect any law,
rule or regulation prohibiting or restricting such sale or requiring any consent
or approval of any person, which shall not have been obtained, to issue the
Securities (except as otherwise provided in this Agreement).

    

    4.2           The
Subscriber’s obligation to purchase the Securities at the Closing at which such
purchase is to be consummated is subject to the fulfillment on or prior to such
Closing of the following conditions, which conditions may be waived at the
option of each Subscriber to the extent permitted by law:

    

    (a)           Representations and
Warranties Correct.  The representations and warranties made by
the Company in Article II hereof shall be true and correct in all material
respects.

    

    (b)           Covenants.  All
covenants, agreements and conditions contained in this Agreement to be performed
by the Company on or prior to the date of such Closing shall have been performed
or complied with in all material respects.

    

    (c)           No Legal Order
Pending.  There shall not then be in effect any legal or other
order enjoining or restraining the transactions contemplated by this
Agreement.

    

    (d)           No Law Prohibiting or
Restricting Such Sale.  There shall not be in effect any law,
rule or regulation prohibiting or restricting such sale or requiring any consent
or approval of any person, which shall not have been obtained, to issue the
Securities (except as otherwise provided in this Agreement).

    

    (e)           Legal
Opinion.  The Placement Agent shall have received an opinion of
counsel to the Company addressed to the Subscribers (which the Placement Agent
may be permitted to rely on as if it were addressed to it) containing certain
opinions to be substantially in the form attached hereto as Exhibit C, which
opinion will be subject to standard qualifications and
assumptions.

    
      
         

      

      
        14

        
          

        

      

      
         

      

    

    (f)           Officer’s
Certificate. The Placement Agent shall have received an Officer’s
Certificate addressed to the Subscribers, signed by the authorized officer of
the Company and dated as of the Closing.  The certificate shall state,
among other things, that the representations and warranties contained herein and
in the Offering Materials are true and accurate in all material respects at such
Closing Date with the same effect as though expressly made at such Closing Date
and the Placement Agent shall be entitled to rely on such representations of the
Company in the Offering Materials as if they were made directly to the Placement
Agent.

    

    V.           REGISTRATION
RIGHTS

    

    5.1          
Definitions.   As
used in this Agreement, the following terms shall have the following
meanings.

    

    (a)           The
term “Holder”
shall mean any holder of Registrable Securities.

    

    (b)           The
terms “register”, “registered” and
“registration”
refer to a registration effected by preparing and filing a registration
statement or similar document in compliance with the Securities Act, and the
declaration or order of effectiveness of such registration statement or
document.

    

    (c)           The
term “Registrable
Securities” shall mean (i) the shares of equity securities issuable upon
conversion of the Notes sold in the Offering (or any successor security) and
upon conversion of the Second Bridge Notes and the Galenica Note; (ii) the
shares of equity securities issuable upon exercise of the Warrants and the
Second Bridge Warrants; and (iii) any shares of equity securities issuable (or
issuable upon the conversion or exercise of any warrant, right or other security
that is issued) pursuant to a dividend or other distribution with respect to or
in replacement of any Securities; provided, however, that securities shall only
be treated as Registrable Securities if and only for so long as they (A) have
not been disposed of pursuant to a registration statement declared effective by
the SEC; (B) have not been sold in a transaction exempt from the registration
and prospectus delivery requirements of the Securities Act so that all transfer
restrictions and restrictive legends with respect thereto are removed upon the
consummation of such sale; (C) are held by a Holder or a permitted transferee of
a Holder pursuant to Section 5.11; and (D) may not be disposed of under Rule 144
under the Securities Act without restriction.

    

    (d)           The
term “Trading
Event” means the first date on which the Company’s Common Stock trades on
a national securities exchange or an Over-the-Counter Bulletin
Board.

    

    (e)           The
term “Second Bridge
Note Financing” means the offer and sale in a private placement of Second
Bridge Notes in an amount of up to $6,000,000 (including over-allotment) and the
Second Bridge Warrants.

    

    (f)           The
term “Second Bridge
Notes” means any convertible promissory notes issued or sold to
purchasers in the Second Bridge Note Financing.

    
      
         

      

      
        15

        
          

        

      

      
         

      

    

    

    (g)           The
term “Second Bridge
Warrants” means any warrants exercisable for shares of Common Stock
issued or sold to purchasers in the Second Bridge Financing.

    

    (h)           The
term “Galenica Note” means the convertible promissory note issued by the Company
to Galenica Ltd. in exchange for the promissory note dated as of December 10,
2008 in the principal amount of $1,000,000.

    

    5.2           Piggyback
Registration.

    

    (a)           The
Company agrees that if, at any time, and from time to time, after the earlier to
occur of (i) an initial public offering of the Company’s equity securities
pursuant to a registration statement declared effective by the Securities and
Exchange Commission (“IPO”) and (ii) a Trading Event, the Board of Directors of
the Company (the “Board”) shall
authorize the filing of a registration statement under the Securities Act (other
than the filing of a registration statement pursuant to the IPO or a
registration statement on Form S-8, Form S-4 or any other form that does not
include substantially the same information as would be required in a form for
the general registration of securities) in connection with the proposed offer of
any of its securities by it or any of its stockholders, the Company shall: (A)
promptly notify each Holder that such registration statement will be filed and
that the Registrable Securities then held by such Holder will be included in
such registration statement at such Holder’s request; (B) cause such
registration statement to cover all of such Registrable Securities issued to
such Holder for which such Holder requests inclusion; (C) use reasonable best
efforts to cause such registration statement to become effective as soon as
practicable; and (D) take all other reasonable action necessary under any
Federal or state law or regulation of any governmental authority to permit all
such Registrable Securities that have been issued to such Holder to be sold or
otherwise disposed of, and will maintain such compliance with each such Federal
and state law and regulation of any governmental authority for the period
necessary for such Holder to promptly effect the proposed sale or other
disposition.

    

    (b)           Notwithstanding
any other provision of this Section 5.2, the Company may at any time, abandon or
delay any registration commenced by the Company.  In the event of such
an abandonment by the Company, the Company shall not be required to continue
registration of shares requested by the Holder for inclusion and the Holder
shall retain the right to request inclusion of shares as set forth
above.

    

    5.3           Demand
Registration.

    

    (a)           Registration on
Request.

    

    (i)           The
Company agrees that, at any time, and from time to time, but at least 180 days
after the earlier to occur of (i) an IPO and (ii) a Trading Event, Holders of a
majority of the Registrable Securities may make a written request that the
Company effect the registration under the Securities Act of outstanding
Registrable Securities; provided that such
requested registration would cover at least 51% of the Registrable Securities
owned by all the Holders at such time; and provided, further, that the
Holders shall be entitled to no more than one such demand
registration.

    
      
         

      

      
        16

        
          

        

      

      
         

      

    

    

    (ii)           The
Company further agrees that if, at any time, and from time to time, after the
Company has qualified for the use of Form S-3 or any successor
form,  one or more of the Holders desire to effect the registration
under the Securities Act on Form S-3 or any successor form (“Short-Form
Registration”) of outstanding Registrable Securities, such Holder(s) may
make a written request that the Company effect a Short-Form Registration; provided that the
aggregate price to the public of the shares as to which such registration is
requested (based on the then current market price and before deducting
underwriting discounts and commissions) would equal or exceed $5,000,000. It is
understood and agreed that the Holders may make good faith requests for
Short-Form Registrations on an unlimited number of occasions; provided further,
that the Company shall not be required to effect more than one Short Form
Registration in any 12-month period.

    

    (iii)           Each
request made by one or more of the Holders pursuant to subsections (i) or (ii)
above (the “Initiating
Holders”) will specify the number of shares of Registrable Securities
proposed to be sold and will also specify the intended method of disposition
thereof. Following receipt of any such request, the Company shall promptly
notify all Holders other than the Initiating Holders of receipt of such request
and the Company shall use best efforts to file, within 60 days of such request,
the registration under the Securities Act of the Registrable Securities which
the Company has been so requested to register in the request by the Initiating
Holders (and in all notices received by the Company from such other Holders
within 30 days after the giving of such notice by the Company), to the extent
necessary to permit the disposition (in accordance with the intended methods
thereof as aforesaid) of the Registrable Securities to be registered. If such
method of disposition shall be an underwritten public offering, the Holders of a
majority of the shares of Registrable Securities to be sold in such offering may
designate the managing underwriter of such offering, subject to the approval of
the Company, which approval shall not be unreasonably withheld or
delayed.  The Holders will be permitted to withdraw Registrable
Securities from a registration at any time prior to the effective date of such
registration; provided the
remaining number of shares of Registrable Securities subject to a requested
registration is not less than the minimum amount required pursuant to this
Section 5.3.

    
      
         

      

      
        17

        
          

        

      

      
         

      

    

    (b)           Limitations on Demand
Registration. Notwithstanding Section 5.3(a), the Company shall not be
obligated to file a registration statement relating to a registration request
pursuant to this Section 5.3 at any time during the 180-day period immediately
following the effective date of any registration statement filed by the Company
(other than on Form S-8 or S-4 or any other form that does not include
substantially the same information as would be required in a form for the
general registration of securities); and if the Board determines, in its good
faith judgment, that the Company (i) should not file any registration statement
otherwise required to be filed pursuant to Section 5.3 or (ii) should withdraw
any such previously filed registration statement because the Board determines,
in its good faith judgment, that the Company is in the possession of material
nonpublic information required to be disclosed in such registration statement or
an amendment or supplement thereto, the disclosure of which in such registration
statement would be materially disadvantageous to the Company (a “Disadvantageous
Condition”), the Company shall be entitled to postpone for the shortest
reasonable period of time (but not exceeding 90 days from the date of the
determination), the filing of such registration statement or, if such
registration statement has already been filed, may suspend or withdraw such
registration statement and shall promptly give the Holders written notice of
such determination, containing a general statement of the reasons for such
postponement and an approximation of the anticipated delay.  Upon the
receipt of any such notice, such Holders shall forthwith discontinue use of the
prospectus contained in such registration statement and, if so directed by the
Company, shall deliver to the Company all copies of the prospectus then covering
such Registrable Securities current at the time of receipt of such notice (or,
if no registration statement has yet been filed, all drafts of the prospectus
covering such Registrable Securities).  If any Disadvantageous
Condition shall cease to exist, the Company shall promptly notify the Holders to
such effect.  If any registration statement shall have been withdrawn,
the Company shall, at such time as it is possible or, if earlier, at the end of
the 90-day period following such withdrawal, file a new registration statement
covering the Registrable Securities that were covered by such withdrawn
registration statement. The Company’s right to delay a request for registration
or to withdraw a registration statement pursuant to this Section 5.3 may not be
exercised more than once in any one-year period.

    

    5.4           Registration
Procedures. Whenever required under this Article V to include Registrable
Securities in a Company registration statement, the Company shall, as
expeditiously as reasonably possible:

    

    (a)           Use
reasonable best efforts to (i) cause such registration statement to become
effective, and (ii) cause such registration statement to remain effective until
the earliest to occur of (A) such date as the sellers of Registrable Securities
(the “Holders”)
have completed the distribution described in the registration statement and (B)
such time that all of such Registrable Securities are no longer, by reason of
Rule 144(k) under the Act, required to be registered for the sale thereof by
such Holders.  The Company will also use its reasonable best efforts
to, during the period that such registration statement is required to be
maintained hereunder, file such post-effective amendments and supplements
thereto as may be required by the Securities Act and the rules and regulations
thereunder or otherwise to ensure that the registration statement does not
contain any untrue statement of material fact or omit to state a fact required
to be stated therein or necessary to make the statements contained therein, in
light of the circumstances under which they are made, not misleading; provided,
however, that if applicable rules under the Securities Act governing the
obligation to file a post-effective amendment permits, in lieu of filing a
post-effective amendment that (i) includes any prospectus required by Section
10(a)(3) of the Securities Act or (ii) reflects facts or events representing a
material or fundamental change in the information set forth in the registration
statement, the Company may incorporate by reference information required to be
included in (i) and (ii) above to the extent such information is contained in
periodic reports filed pursuant to Section 13 or 15(d) of the Exchange Act in
the registration statement. In the event that the Company becomes qualified for
the use of Form S-3 or any successor form at a time when any registration
statement on any other Form which includes Registrable Securities is required to
be maintained hereunder, the Company shall, upon the request of any Selling
Holder, subject to Section 5.5, (i) as expeditiously as reasonably possible, use
reasonable best efforts to cause a Short-Form Registration covering such
Registrable Securities to become effective and (ii) comply with each of the
other requirements of this Section 5.4 which may applicable thereto. Upon the
effectiveness of such Short-Form Registration, the Company shall be relieved of
its obligations hereunder to keep in effect the registration statement which
initially covered the Registrable Securities included in such Short-Form
Registration.

    
      
         

      

      
        18

        
          

        

      

      
         

      

    

    

    (b)           Prepare
and file with the SEC such amendments and supplements to such registration
statement, and the prospectus used in connection with such registration
statement, as may be necessary to comply with the provisions of the Securities
Act with respect to the disposition of all securities covered by such
registration statement.

    

    (c)           Furnish
to the selling Holders such numbers of copies of a prospectus, including a
preliminary prospectus as amended or supplemented from time to time, in
conformity with the requirements of the Securities Act, and such other documents
as they may reasonably request in order to facilitate the disposition of
Registrable Securities owned by them.

    

    (d)           Use
reasonable best efforts to register and qualify the securities covered by such
registration statement under such other federal or state securities laws of such
jurisdictions as shall be reasonably requested by the selling Holders; provided,
however, that the Company shall not be required in connection therewith or as a
condition thereto to qualify to do business or to file a general consent to
service of process in any such states or jurisdictions, unless the Company is
already subject to service in such jurisdiction and except as may be required by
the Securities Act.

    

    (e)           In
the event of any underwritten public offering, enter into and perform its
obligations under an underwriting agreement, in usual and customary form, with
the managing underwriter of such offering.  Each selling Holder
participating in such underwriting shall also enter into and perform its
obligations under such an agreement.

    

    (f)           Notify
each Holder of Registrable Securities covered by such registration statement, at
any time when a prospectus relating thereto is required to be delivered under
the Securities Act, (i) when the registration statement or any post-effective
amendment and supplement thereto has become effective; (ii) of the issuance by
the SEC of any stop order or the initiation of proceedings for that purpose (in
which event the Company shall make every effort to obtain the withdrawal of any
order suspending effectiveness of the registration statement at the earliest
possible time or prevent the entry thereof); (iii) of the receipt by the Company
of any notification with respect to the suspension of the qualification of the
Registrable Securities for sale in any jurisdiction or the initiation of any
proceeding for such purpose; and (iv) of the happening of any event as a result
of which the prospectus included in such registration statement, as then in
effect, includes an untrue statement of a material fact or omits to state a
material fact required to be stated therein or necessary to make the statements
therein not misleading in the light of the circumstances then existing (and each
Holder agrees to suspend any trading under the Registration Statement until such
condition is abated).

    

    (g)           Cause
all such Registrable Securities registered hereunder to be listed on each
securities exchange or quotation service on which similar securities issued by
the Company are then listed or quoted or, if no such similar securities are
listed or quoted on a securities exchange or quotation service, apply for
qualification and use reasonable best efforts to qualify such Registrable
Securities for inclusion on a national securities exchange or the
Over-the-Counter Bulletin Board.

    
      
         

      

      
        19

        
          

        

      

      
         

      

    

    

    (h)           Provide
a transfer agent and registrar for all Registrable Securities registered
pursuant hereunder and CUSIP number for all such Registrable Securities, in each
case not later than the effective date of such registration.

    

    (i)           Cooperate
with the selling Holders and the managing underwriters, if any, to facilitate
the timely preparation and delivery of certificates representing the Registrable
Securities to be sold, which certificates will not bear any restrictive legends;
and enable such Registrable Securities to be in such denominations and
registered in such names as the managing underwriters, if any, shall request at
least two business days prior to any sale of the Registrable Securities to the
underwriters.

     

    5.5           Furnish
Information.  It shall be a condition precedent to the
obligation of the Company to take any action pursuant to this Article V with
respect to the Registrable Securities of any Holder that such Holder shall
furnish to the Company such information regarding the Holder, the Registrable
Securities held by the Holder, and the intended method of disposition of such
securities as shall be reasonably required by the Company to effect the
registration of such Holder’s Registrable Securities.

     

    5.6           Registration
Expenses.  The Company shall bear and pay all expenses incurred
in connection with any registration, filing or qualification of Registrable
Securities with respect to registrations pursuant to Sections 5.2 or 5.3 for
each Holder, including (without limitation) all registration, filing, and
qualification fees, printers and accounting fees relating or apportionable
thereto (“Registration
Expenses”), but excluding underwriting discounts and commissions relating
to Registrable Securities and excluding any professional fees or costs of
accounting, financial or legal advisors to any of the Holders.

    

    5.7           Underwriting
Requirements.  In connection with any offering involving an
underwriting of shares of the Company’s capital stock, the Company shall not be
required under Section 5.2 to include any of the Holders’ Registrable Securities
in such underwriting unless they accept the terms of the underwriting as agreed
upon between the Company and the underwriters selected by it (or by other
persons entitled to select the underwriters), and then only in such quantity as
the underwriters determine in their sole discretion will not jeopardize the
success of the offering by the Company.  If the total amount of
securities, including Registrable Securities, requested by stockholders to be
included in such offering exceeds the amount of securities sold other than by
the Company that the underwriters determine in their sole discretion is
compatible with the success of the offering, then the Company shall be required
to include in the offering only that number of such securities, including
Registrable Securities, which the underwriters determine in their sole
discretion will not jeopardize the success of the offering (the securities so
included to be apportioned pro rata among the selling Holders according to the
total amount of securities entitled to be included therein owned by each selling
Holder or in such other proportions as shall mutually be agreed to by such
selling Holders).  For purposes of the preceding parenthetical
concerning apportionment, for any selling Holder who is a holder of Registrable
Securities and is a partnership or corporation, the partners, retired partners
and stockholders of such Holder, or the estates and family members of any such
partners and retired partners and any trusts for the benefit of any of the
foregoing persons shall be deemed to be a single “selling Holder”, and any
pro-rata reduction with respect to such “selling Holder” shall be based upon the
aggregate amount of shares carrying registration rights owned by all entities
and individuals included in such “selling Holder”, as defined in this
sentence.

    
      
         

      

      
        20

        
          

        

      

      
         

      

    

    

    5.8           Delay of
Registration.  No Holder shall have any right to obtain or seek
an injunction restraining or otherwise delaying any such registration as the
result of any controversy that might arise with respect to the interpretation or
implementation of this Article V.

    

    5.9           Indemnification.  In
the event that any Registrable Securities are included in a registration
statement under this Article V:

    

    (a)           To
the extent permitted by law, the Company will indemnify and hold harmless each
Holder, any underwriter (as defined in the Securities Act) for such Holder and
each person, if any, who controls such Holder or underwriter within the meaning
of the Securities Act or the Exchange Act, against any losses, claims, damages,
or liabilities (joint or several) to which they may become subject under the
Securities Act, or the Exchange Act, insofar as such losses, claims, damages, or
liabilities (or actions in respect thereof) arise out of or are based upon any
of the following statements, omissions or violations (collectively a
“Violation”):  (i) any untrue statement or alleged untrue statement of
a material fact contained in such registration statement, including any
preliminary prospectus or final prospectus contained therein or any amendments
or supplements thereto, (ii) the omission or alleged omission to state therein a
material fact required to be stated therein, or necessary to make the statements
therein not misleading, or (iii) any violation or alleged violation by the
Company of the Securities Act, the Exchange Act, or any rule or regulation
promulgated under the Securities Act, or the Exchange Act, and the Company will
pay to each such Holder, underwriter or controlling person, as incurred, any
legal or other expenses reasonably incurred by them in connection with
investigating or defending any such loss, claim, damage, liability, or action;
provided, however, that the indemnity agreement contained in this Section 5.9(a)
shall not apply to amounts paid in settlement of any such loss, claim, damage,
liability, or action if such settlement is effected without the consent of the
Company (which consent shall not be unreasonably withheld), nor shall the
Company be liable in any such case for any such loss, claim, damage, liability,
or action to the extent that it arises out of or is based upon a Violation which
occurs in reliance upon and in conformity with written information furnished
expressly for use in connection with such registration by any such Holder,
underwriter or controlling person or a violation of any provision of this
Agreement by a Holder.

    

    
      
         

      

      
        21

        
          

        

      

      
         

      

    

    (b)           To
the extent permitted by law, each Selling Holder will indemnify and hold
harmless the Company, each of its directors, each of its officers, each person,
if any, who controls the Company within the meaning of the Securities Act, any
underwriter, any other Holder selling securities in such registration statement
and any controlling person of any such underwriter or other Holder, against any
losses, claims, damages, or liabilities (joint or several) to which any of the
foregoing persons may become subject, under the Securities Act, or the Exchange
Act, insofar as such losses, claims, damages, or liabilities (or actions in
respect thereto) arise out of or are based upon any Violation, in each case to
the extent (and only to the extent) that such Violation occurs in reliance upon
and in conformity with written information furnished by such Holder expressly
for use in connection with such registration or a violation of any provision of
this Agreement by a Holder; and each such Holder will pay, as incurred, any
legal or other expenses reasonably incurred by any person intended to be
indemnified pursuant to this Section 5.9(b), in connection with investigating or
defending any such loss, claim, damage, liability, or action; provided, however, that the
indemnity agreement contained in this Section 5.9(b) shall not apply to amounts
paid in settlement of any such loss, claim, damage, liability or action if such
settlement is effected without the consent of the Holder, which consent shall
not be unreasonably withheld; provided, further, that, in no
event shall any indemnity under this Section 5.9(b) exceed the greater of the
cash value of the (i) gross proceeds from the offering received by such Holder
or (ii) such Holder’s investment pursuant to this Agreement as set forth on the
signature page attached hereto.

    

    (c)           Promptly
after receipt by an indemnified party under this Section 5.9 of notice of the
commencement of any action (including any governmental action), such indemnified
party shall, if a claim in respect thereof is to be made against any
indemnifying party under this Section 5.9, deliver to the indemnifying party a
written notice of the commencement thereof and the indemnifying party shall have
the right to participate in, and, to the extent the indemnifying party so
desires, jointly with any other indemnifying party similarly notified, to assume
the defense thereof with counsel selected by the indemnifying party and approved
by the indemnified party (whose approval shall not be unreasonably withheld);
provided, however, that an indemnified party (together with all other
indemnified parties which may be represented without conflict by one counsel)
shall have the right to retain one separate counsel, with the fees and expenses
to be paid by the indemnifying party, if representation of such indemnified
party by the counsel retained by the indemnifying party would be inappropriate
due to actual or potential differing interests between such indemnified party
and any other party represented by such counsel in such
proceeding.  The failure to deliver written notice to the indemnifying
party within a reasonable time of the commencement of any such action, if
prejudicial to its ability to defend such action, shall relieve such
indemnifying party of any liability to the indemnified party under this Section
5.9, but the omission so to deliver written notice to the indemnifying party
will not relieve it of any liability that it may have to any indemnified party
otherwise than under this Section 5.9.

    

    (d)           If
the indemnification provided for in this Section 5.9 is held by a court of
competent jurisdiction to be unavailable to an indemnified party with respect to
any loss, liability, claim, damage, or expense referred to therein, then the
indemnifying party, in lieu of indemnifying such indemnified party hereunder,
shall contribute to the amount paid or payable by such indemnified party as a
result of such loss, liability, claim, damage, or expense in such proportion as
is appropriate to reflect the relative fault of the indemnifying party on the
one hand and of the indemnified party on the other in connection with the
statements or omissions that resulted in such loss, liability, claim, damage, or
expense as well as any other relevant equitable considerations.  The
relative fault of the indemnifying party and of the indemnified party shall be
determined by reference to, among other things, whether the untrue or alleged
untrue statement of a material fact or the alleged omission to state a material
fact relates to information supplied by the indemnifying party or by the
indemnified party and the parties’ relative intent, knowledge, access to
information, and opportunity to correct or prevent such statement or
omission.

    
      
         

      

      
        22

        
          

        

      

      
         

      

    

    

    (e)           Notwithstanding
the foregoing, to the extent that the provisions on indemnification and
contribution contained in the underwriting agreement entered into in connection
with the underwritten public offering are in conflict with the foregoing
provisions, the provisions in the underwriting agreement shall
control.

    

    (f)           The
obligations of the Company and Holders under this Section 5.9 shall survive the
completion of any offering of Registrable Securities in a registration statement
under this Article V, and otherwise.

    

    5.10         Reports Under Securities
Exchange Act of 1934.  With a view to making available to the
Holders the benefits of Rule 144 and any other rule or regulation of the SEC
that may at any time permit a Holder to sell securities of the Company to the
public without registration or pursuant to a registration on Form S-3, the
Company agrees to:

    

    (a)           make
and keep public information available, as those terms are understood and defined
in Rule 144, at all times after 90 days after the effective date of the
IPO  or Trading Event by the Company;

    

    (b)           file
with the SEC in a timely manner all reports and other documents required of the
Company under the Securities Act and the Exchange Act; and

    

    (c)           furnish
to any Holder, so long as the Holder owns any Registrable Securities, forthwith
upon request (i) a copy of the most recent annual or quarterly report of the
Company and such other reports and documents so filed by the Company, and (ii)
such other information as may be reasonably requested in availing any Holder of
any rule or regulation of the SEC which permits the selling of any such
securities without registration or pursuant to such form.

    

    5.11         Permitted
Transferees.  The rights to cause the Company to register
Registrable Securities granted to the Holders by the Company under this Article
V may be assigned in full by a Holder in connection with a transfer by such
Holder of its Registrable Securities if: (a) such transferee agrees to
comply with the terms and provisions of this Agreement; (b) such transfer
is otherwise in compliance with this Agreement; (c) such transfer is
otherwise effected in accordance with applicable securities laws; and (d) such
Holder transfers at least 51% of its shares of Registrable Securities to the
transferee.  Except as specifically permitted by this Section 5.11,
the rights of a Holder with respect to Registrable Securities as set out herein
shall not be transferable to any other Person, and any attempted transfer shall
cause all rights of such Holder therein to be forfeited.

    

    5.12         Termination of Registration
Rights.  The right of any Holder to request or demand inclusion
in any registration pursuant to Section 5.2 and Section 5.3 shall terminate if
all shares of Registrable Securities held by such Holder may immediately be sold
under Rule 144(k) without restriction.

    
      
         

      

      
        23

        
          

        

      

      
         

      

    

    

    VI.           MISCELLANEOUS

    

    6.1           Any
notice or other communication given hereunder shall be deemed sufficient if in
writing and sent by registered or certified mail, return receipt requested, or
delivered by hand against written receipt therefor, addressed as
follows:

    

    if to the
Company, to it at:

    

    CorMedix
Inc.

    86 Summit
Avenue, Suite 301

    Summit,
NJ 07901-3647

    Facsimile:  (908)
522-9199

    Attn:  President

    

    With a
copy to:

    

    Olshan
Grundman Frome Rosenzweig & Wolosky LLP

    Park
Avenue Tower

    65 East
55th Street

    New York,
NY 10022

    Facsimile:
(212) 451-2222

    Attn:
Yehuda Markovits,
Esq.

    

    Paramount
BioCapital, Inc.

    787
Seventh Avenue, 48th
Floor

    New York,
NY 10019

    Facsimile:  (212)
554-4355

    Attn:
Basil Christakos

    

    if to the
Subscriber, to the Subscriber’s address indicated on the signature page of this
Agreement.

    

    Notices
shall be deemed to have been given or delivered on the date of mailing, except
notices of change of address, which shall be deemed to have been given or
delivered when received.

    

    6.2           Except
as otherwise expressly provided herein, any term of this Agreement may be
amended and the observance of any term of this Agreement may be waived (either
generally or in a particular instance, either retroactively or prospectively and
either for a specified period of time or indefinitely) with the written consent
of the Company and (a) subscribers holding Notes evidencing at least sixty six
and two-thirds percent (66 2⁄3%) of the then outstanding Principal Loan Amount of
the Notes issued pursuant to this Agreement and substantially similar
agreements, so long as the Notes are outstanding; and (b) holders of sixty six
and two-thirds percent (66 2⁄3%) of the Registrable Securities issued upon
conversion of the Notes, if the Notes are no longer outstanding.  Any
amendment or waiver effected in accordance with this Section 6.2 shall be
binding upon the Subscriber and the Company (even if the Subscriber does not
consent to such amendment or waiver), and upon the effectuation of each such
amendment or waiver, the Company shall promptly give written notice thereof to
the Subscriber if the Subscriber has not previously consented thereto in
writing. Notwithstanding the foregoing, Sections 2.17, 5.1(c) and 5.1(e), (f),
(g) and (h) of this Agreement shall not be amended nor the observance of any
term thereof waived without the written consent of (x) subscribers holding Notes
and, Second Bridge Notes and the Galenica Note evidencing at least sixty-six and
two-thirds percent (662⁄3%), of the outstanding aggregate principal amount of the
Notes, the Second Bridge Notes and the Galenica Note, so long as the Notes, the
Second Bridge Notes and the Galenica Note are outstanding; and (y) holders of
sixty-six and two-thirds percent (662⁄3%), in the aggregate, of the Registrable
Securities issued upon conversion of the Notes, the Second Bridge Notes and the
Galenica Note, if the Notes, the Second Bridge Notes and the Galenica Note are
no longer outstanding.

    
      
         

      

      
        24

        
          

        

      

      
         

      

    

    

    6.3           Subject
to the provisions of Section 5.11, this Agreement shall be binding upon and
inure to the benefit of the parties hereto and to their respective heirs, legal
representatives, successors and assigns.  This Agreement sets forth
the entire agreement and understanding between the parties as to the subject
matter hereof and merges and supersedes all prior discussions, agreements and
understandings of any and every nature among them.

    

    6.4           Upon
the execution and delivery of this Agreement by the Subscriber, this Agreement
shall become a binding obligation of the Subscriber with respect to the purchase
of Notes as herein provided, subject, however, to the right hereby reserved by
the Company to enter into the same agreements with other subscribers and to add
and/or delete other persons as subscribers.

    

    6.5           NOTWITHSTANDING
THE PLACE WHERE THIS AGREEMENT MAY BE EXECUTED BY ANY OF THE PARTIES HERETO, THE
PARTIES EXPRESSLY AGREE THAT ALL THE TERMS AND PROVISIONS HEREOF SHALL BE
CONSTRUED IN ACCORDANCE WITH AND GOVERNED BY THE SUBSTANTIVE AND PROCEDURAL LAWS
OF THE STATE OF NEW YORK WITHOUT REGARD TO SUCH STATE’S PRINCIPLES OF CONFLICTS
OF LAW.  IN THE EVENT THAT A JUDICIAL PROCEEDING IS NECESSARY, THE
SOLE FORUM FOR RESOLVING DISPUTES ARISING OUT OF OR RELATING TO THIS AGREEMENT
IS THE STATE AND FEDERAL COURTS SITTING IN THE BOROUGH OF MANHATTAN, COUNTY OF
NEW YORK.  THE PARTIES HEREBY IRREVOCABLY CONSENT TO THE JURISDICTION
OF SUCH COURTS AND AGREE TO SAID VENUE.

    

    6.6           The
holding of any provision of this Agreement to be invalid or unenforceable by a
court of competent jurisdiction shall not affect any other provision of this
Agreement, which shall remain in full force and effect.  If any
provision of this Agreement shall be declared by a court of competent
jurisdiction to be invalid, illegal or incapable of being enforced in whole or
in part, such provision shall be interpreted so as to remain enforceable to the
maximum extent permissible consistent with applicable law and the remaining
conditions and provisions or portions thereof shall nevertheless remain in full
force and effect and enforceable to the extent they are valid, legal and
enforceable, and no provisions shall be deemed dependent upon any other covenant
or provision unless so expressed herein.

    
      
         

      

      
        25

        
          

        

      

      
         

      

    

    

    6.7           It
is agreed that a waiver by either party of a breach of any provision of this
Agreement shall not operate, or be construed, as a waiver of any subsequent
breach by that same party.

    

    6.8           The
parties agree to execute and deliver all such further documents, agreements and
instruments and take such other and further action as may be necessary or
appropriate to carry out the purposes and intent of this Agreement.

    

    6.9           This
Agreement may be executed in two or more counterparts each of which shall be
deemed an original, but all of which shall together constitute one and the same
instrument.

    

    6.10         Nothing
in this Agreement shall create or be deemed to create any rights in any person
or entity not a party to this Agreement, except (a) for the holders of
Registrable Securities; (b) for the Placement Agent pursuant to Sections 1.6(a),
1.12, and 1.24 hereof, (c) for the indemnified parties (including without
limitation the Placement Agent and its sub agents, if any) pursuant to Section
5.9 hereof; and (d) that the Placement Agent may rely upon the representations
and acknowledgements of the Subscriber in Articles I and VII hereof and the
representations and warranties of the Company in Article II hereof.

    

    Remainder of Page Intentionally Left
Blank.

    
      
         

      

      
        26

        
          

        

      

      
         

      

    

    

    VII.           CONFIDENTIAL INVESTOR
QUESTIONNAIRE

    

    7.1           The
Subscriber represents and warrants that he, she or it comes within one category
marked below, and that for any category marked, he, she or it has truthfully set
forth, where applicable, the factual basis or reason the Subscriber comes within
that category.  ALL INFORMATION IN RESPONSE TO THIS SECTION WILL BE
KEPT STRICTLY CONFIDENTIAL except as otherwise required by law.  The
undersigned agrees to furnish any additional information which the Company deems
necessary in order to verify the answers set forth below.

    

    
      
        
          
            	
                    Category
      A ____

                  	
                    The
      undersigned is an individual (not a partnership, corporation, etc.) whose
      individual net worth, or joint net worth with his or her spouse, presently
      exceeds $1,000,000.

                  
	 
      	 
      
	 
      	
                    Explanation:  In
      calculating net worth you may include equity in personal property and real
      estate, including your principal residence, cash, short-term investments,
      stock and securities.  Equity in personal property and real
      estate should be based on the fair market value of such property less debt
      secured by such property.

                  
	 
      	 
      
	
                    Category
      B ____

                  	
                    The
      undersigned is an individual (not a partnership, corporation, etc.) who
      had an income in excess of $200,000 in each of the two most recent years,
      or joint income with his or her spouse in excess of $300,000 in each of
      those years (in each case including foreign income, tax exempt income and
      full amount of capital gains and losses but excluding any income of other
      family members and any unrealized capital appreciation) and has a
      reasonable expectation of reaching the same income level in the current
      year.

                  
	  
      	 
      
	
                    Category
      C ____

                  	
                    The
      undersigned is a director or executive officer of the Company which is
      issuing and selling the Securities.

                  
	 
      	 
      
	
                    Category
      D ____

                  	
                    The
      undersigned is a bank; a savings and loan association; insurance company;
      registered investment company; registered business development company;
      licensed small business investment company (“SBIC”); or employee benefit
      plan within the meaning of Title 1 of ERISA and (a) the investment
      decision is made by a plan fiduciary which is either a bank, savings and
      loan association, insurance company or registered investment advisor, or
      (b) the plan has total assets in excess of $5,000,000 or (c) is a self
      directed plan with investment decisions made solely by persons that are
      accredited investors. (describe
      entity)

                  
	 
      	 
      
	 
      	 
      

          

        

      

    

    
      
         

      

      
        27

        
          

        

      

      
         

      

    

    

    
      
        
          
            
              
                
                  
                    
                      
                        
                          
                            
                              
                                	
                                        Category
      E ____

                                      	
                                        The
      undersigned is a private business development company as defined in
      section 202(a)(22) of the Investment Advisors Act of 1940. (describe
      entity)

                                      
	 
      	 
      
	 
      	 
      
	 
      	 
      
	
                                        Category
      F ____

                                      	
                                        The
      undersigned is either a corporation, partnership, Massachusetts business
      trust, or non-profit organization within the meaning of Section 501(c)(3)
      of the Internal Revenue Code, in each case not formed for the specific
      purpose of acquiring the Notes and with total assets in excess of
      $5,000,000.(describe
      entity)

                                      
	 
      	 
      
	 
      	 
      
	 	 
	
                                        Category
      G ____

                                      	
                                        The
      undersigned is a trust with total assets in excess of $5,000,000, not
      formed for the specific purpose of acquiring the Securities, where the
      purchase is directed by a “sophisticated investor” as defined in
      Regulation 506(b)(2)(ii) under the Act.

                                      
	 
      	 
      
	
                                        Category
      H ____

                                      	
                                        The
      undersigned is an entity (other than a trust) in which all of the equity
      owners are “accredited investors” within one or more of the above
      categories.  If relying upon this Category alone, each equity
      owner must complete a separate copy of this Agreement.  (describe
      entity)

                                      
	 
      	 
      
	 
      	 
      
	
                                        Category
      I ____

                                      	
                                        The
      undersigned is not within any of the categories above and is therefore not
      an accredited
investor.

                                      

                              

                            

                          

                        

                      

                    

                  

                

              

            

          

        

      

    

    

    The
undersigned agrees that the undersigned will notify the Company at any time on
or prior to the Closing Date in the event that the representations and
warranties in this Agreement shall cease to be true, accurate and
complete.

    
      
         

      

      
        28

        
          

        

      

      
         

      

    

    

    7.2           SUITABILITY. (please
answer each question)

    

    (a)  For
an individual Subscriber, please describe your current employment, including the
company by which you are employed and its principal business:

     

      
        

      

    

    
      
        

      

    

    
      
        

      

      
        

      

    

     

    (b)  For
an individual Subscriber, please describe any college or graduate degrees held
by you:

     

    
      
        

      

      
        

      

      
        

      

    

     

    (c)  For
all Subscribers, please list types of prior investments:

     

    
      
        

      

    

    
      
        

      

      
        

      

    

     

    (d)           For
all Subscribers, please state whether you have you participated in other private placements
before:

    

    YES_______                                   NO_______

    

    (e) If
your answer to question 8.2(d) above was “YES”, please indicate frequency of
such prior participation in private placements
of:

     

    
      
        
          
            
              	 
      	
                      Public

                    	 	Private	
                       

                    	
                      Public or Private

                    
	  	
                      Companies

                    	 	
                      Companies

                    	  	
                      Biopharmaceutical Companies

                    
	 
      	 
      	 	 
      	 
      	 
      
	
                      Frequently

                    	______________ 
      	 	______________ 
      	 
      	______________ 
      
	
                      Occasionally

                    	______________ 
      	 	______________ 
      	 
      	______________ 
      
	
                      Never

                    	______________	 	______________ 
      	 
      	______________ 
      

            

          

        

      

    

    

    (f) For
individual Subscribers, do you expect your current level of income to
significantly decrease in the foreseeable future:

    

    YES_______                                   NO_______

    
      
         

      

      
        29

        
          

        

      

      
         

      

    

    

    (g)  For
trust, corporate, partnership and other institutional Subscribers, do you expect
your total assets to significantly decrease in the foreseeable
future:

    

    YES_______                                   NO_______

    

    (h)  For
all Subscribers, do you have any other investments or contingent liabilities
which you reasonably anticipate could cause you to need sudden cash requirements
in excess of cash readily available to you:

    

    YES_______                                   NO_______

    

    (i)  For
all Subscribers, are you familiar with the risk aspects and the non-liquidity of
investments such as the securities for which you seek to subscribe?

    

    YES_______                                   NO_______

    

    (j)  For
all Subscribers, do you understand that there is no guarantee of financial
return on this investment and that you run the risk of losing your entire
investment?

    

    YES_______                                   NO_______

    

    7.3           MANNER IN WHICH TITLE IS TO
BE HELD. (circle
one)

    

      (a)         Individual
Ownership

      (b)         Community
Property

      (c)         Joint
Tenant with Right of

      Survivorship (both
parties

      must sign)

      (d)         Partnership*

      (e)         Tenants
in Common

      (f)          Company*

      (g)         Trust*

      (h)         Other

    

    *If Securities are being subscribed for
by an entity, the attached Certificate of Signatory must also be
completed.

    

    7.4           NASD
AFFILIATION.

    

    Are you
affiliated or associated with an NASD member firm (please check
one):

    

    Yes
_________                                                      No
__________

    

    If Yes,
please describe:

    _________________________________________________________

    _________________________________________________________

    
      
         

      

      
        30

        
          

        

      

      
         

      

    

    

    *If
Subscriber is a Registered Representative with an NASD member firm, have the
following acknowledgment signed by the appropriate party:

    

    The
undersigned NASD member firm acknowledges receipt of the notice required by NASD
Rule 3050.

     

    
      
        
          
            	 
      	 
      	 
      	 
      	 
	 
      	 
      	 
      	 
	
                    Name
      of NASD Member Firm

                  	 
      	 
      	 
	 
      	 
      	 
      	 
      	 
	
                    By:

                  	 
      	 
      	
                    Date:
      

                  	 
	 
      	
                    Authorized
      Officer

                  	 
      	 
      	 

          

        

      

    

    

    7.5           The
undersigned is informed of the significance to the Company of the foregoing
representations and answers contained in the Confidential Investor Questionnaire
contained in this Article VIII and such answers have been provided under the
assumption that the Company will rely on them.

    

    
      
        
          
            
              
                
                  
                    	
                            Signature:

                          	 
      
	 
      	 
      
	 
      	 
      
	 
      	
                            (If
      purchased jointly)

                          
	 
      	 
      
	
                            Print Name:

                          	 
      
	 
      	 
      
	 
      	 
      
	 
      	
                            (If
      purchased jointly)

                          
	 
      	 
      
	
                            Date:

                          	 
      

                  

                

              

            

          

        

      

    

    
      
         

      

      
        31

        
          

        

      

      
         

      

    

    AGGREGATE
PRINCIPAL AMOUNT OF NOTES = $ _______________ (TOTAL
INVESTMENT)

    

    
      
        
          
            
              
                
                  
                    
                      
                        
                          
                            
                              
                                
                                  
                                    
                                      
                                        
                                          
                                            
                                              
                                                
                                                  
                                                    
                                                      	 
      	 
      	 
      
	
                                                              Signature

                                                            	 
      	
                                                              Signature
      (if purchasing jointly)

                                                            
	 	 	 
	 
      	 
      	 
      
	
                                                              Name
      Typed or Printed

                                                            	 
      	
                                                              Name
      Typed or Printed

                                                            
	 
      	 
      	 
      
	 
      	 
      	 
      
	
                                                              Entity
      Name

                                                            	 
      	
                                                              Entity
      Name

                                                            
	 
      	 
      	 
      
	 
      	 
      	 
      
	
                                                              Address

                                                            	 
      	
                                                              Address

                                                            
	 
      	 
      	 
      
	 
      	 
      	 
      
	
                                                              City,
      State and Zip Code

                                                            	 
      	
                                                              City,
      State and Zip Code

                                                            
	 	 	 
	 
      	 
      	 
      
	
                                                              Telephone-Business

                                                            	 
      	
                                                              Telephone—Business

                                                            
	 
      	 
      	 
      
	 
      	 
      	 
      
	
                                                              Telephone-Residence

                                                            	 
      	
                                                              Telephone—Residence

                                                            
	 
      	 
      	 
      
	 
      	 
      	 
      
	
                                                              Facsimile-Business

                                                            	 
      	
                                                              Facsimile—Business

                                                            
	 	 	 
	 
      	 
      	 
      
	
                                                              Facsimile-Residence

                                                            	 
      	
                                                              Facsimile—Residence

                                                            
	 	 	 
	 
      	 
      	 
      
	
                                                              Tax
      ID # or Social Security #

                                                            	 
      	
                                                              Tax
      ID # or Social Security
#

                                                            

                                                    

                                                  

                                                

                                              

                                            

                                          

                                        

                                      

                                    

                                  

                                

                              

                            

                          

                        

                      

                    

                  

                

              

            

          

        

      

    

    

    Name in
which securities should be issued:                                                                                     

    

    Dated:          
                                ,
200__

    
      
         

      

      
        
        

        
          

        

      

      
         

      

    

    

    This Note and Warrant Purchase
Agreement is agreed to and accepted as of ___________________________ ,
200__.

    

    
      
        
          	
                  CORMEDIX
      INC.

                
	 
      
	
                  By:

                	 
      
	
                  Name:  Bruce
      Cooper, M.D.

                
	
                  Title: 
      President and Chief Executive
Officer

                

        

      

    

    
      
         

      

      
        
        

        
          

        

      

      
         

      

    

    CERTIFICATE
OF SIGNATORY

    

    (To be
completed if Securities are

    being
subscribed for by an entity)

    

    I,___________________________________________,
am the___________________________________________ of
__________________________________________ (the “Entity”).

    

    I certify
that I am empowered and duly authorized by the Entity to execute and carry out
the terms of the Note and Warrant Purchase Agreement and to purchase and hold
the Securities, and certify further that the Note and Warrant Purchase Agreement
has been duly and validly executed on behalf of the Entity and constitutes a
legal and binding obligation of the Entity.

    

    IN
WITNESS WHEREOF, I have set my hand this ________ day of
_________________,______

    

    
      
        	 
      
	
                (Signature)THIS NOTE
AND THE SECURITIES ISSUABLE UPON CONVERSION HEREOF HAVE NOT BEEN REGISTERED
UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”),
APPLICABLE STATE SECURITIES LAWS, OR APPLICABLE LAWS OF ANY FOREIGN
JURISDICTION.  THIS NOTE AND SUCH SECURITIES HAVE BEEN ACQUIRED FOR
INVESTMENT AND NOT WITH A VIEW TO DISTRIBUTION OR RESALE, AND MAY NOT BE
OFFERED, SOLD, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED IN THE ABSENCE OF
AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT AND ANY APPLICABLE
STATE SECURITIES LAWS AND IN THE ABSENCE OF COMPLIANCE WITH APPLICABLE LAWS OF
ANY FOREIGN JURISDICTION, OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY
THAT SUCH REGISTRATION IS NOT REQUIRED AND SUCH FOREIGN JURISDICTION LAWS HAVE
BEEN SATISFIED.

    

    CORMEDIX
INC.

    AMENDED
& RESTATED CONVERTIBLE PROMISSORY NOTE

    

    
      	 
      	
              Summit,
      NJ

            
	
              $___________

            	
              ____________  ___,
      2008, originally issued on _______  __,
  2007

            

    

    

    1.           Principal and
Interest

    

    CORMEDIX INC. (the “Company”), a Delaware
corporation, for value received, hereby promises to pay to the order of
______________________, or his, her or its assigns (“Holder”), in lawful
money of the United States of America at the address for notices to Holder set
forth in the applicable Purchase Agreement (as defined below) (or such other
address as Holder shall provide to the Company in writing pursuant hereto), the
principal amount of ____________ dollars ($___________), together with interest
as set forth below.

    

    The Company promises to pay interest on
the unpaid principal amount from the date hereof until July 31, 2009 at the rate
of ten percent (10%) per annum, or such lesser rate as shall be the maximum rate
allowable under applicable law, and from August 1, 2009 until such principal
amount is paid in full at the rate of twelve percent (12%) per annum, or such
lesser rate as shall be the maximum rate allowable under applicable
law.  Interest from the date hereof shall be computed on the basis of
a 360-day year of twelve 30-day months, shall compound annually and shall be
accrued and added to principal on an annual basis.  Unless converted,
all unpaid principal and unpaid accrued interest on this Note shall be due and
payable on July 31, 2010; provided however, that upon an Event of Default (as
defined herein) during the Initial Term or the Extended Term, the interest rate
on this Note shall be increased to fourteen percent (14%) per annum, or such
lesser rate as shall be the maximum rate allowable under applicable law. during
the term of the default. For purposes of this Note, an “Event of Default” shall
occur if (i) the Company shall default in the payment on the Note, when and as
the same shall become due and payable; or (ii) the Company shall default in the
due observance or performance of any material covenant, condition or agreement
on the part of the Company contained in this Note or the Purchase Agreement, and
any such default shall continue for a period of five (5) business days after the
Company receives written notice thereof.

    
      
         

      

      
        
        

        
          

        

      

      
         

      

    

    This Note is being issued pursuant to
that certain Note and Warrant Purchase Agreement between the Company and the
Holder, dated as of _________  ___, 2007 and amended on the date
hereof (the “Purchase
Agreement”), and is subject to its terms.  Capitalized terms
used herein but not defined shall have the meanings given to such terms in the
Purchase Agreement.  This Note is being issued together with a series
of convertible promissory notes issued by the Company in connection with an
offering described in the Company’s Confidential Offering Memorandum (the “Memorandum”) dated
June 15, 2007 and Supplement No. 1 to the Memorandum dated August 14, 2007 (such
notes shall be collectively referred to as the “Bridge
Notes”).  The Bridge Notes, the Second Bridge Notes and the
Galenica Note (each as defined in the Purchase Agreement) rank pari passu in
right of payment with all other existing indebtedness of the Company and,
pursuant to Section 2.17 of the Purchase Agreement, no new indebtedness which is
secured or senior in right of payment to the Bridge Notes, the Second Bridge
Notes and the Galenica Note may be issued by the Company without the consent of
the holders of Bridge Notes, the holders of Second Bridge Notes and the holder
of the Galenica Note collectively, consenting together as one group,
representing at least sixty-six and two-thirds percent (66 2⁄3%) of the aggregate
principal amount of all outstanding Bridge Notes, Second Bridge Notes and the
Galenica Note.  No consent of the holders of Bridge Notes, Second
Bridge Notes or the Galenica Note will be required for issuances by the Company
of unsecured indebtedness that ranks pari passu in right of payment with, or
junior in right of payment to, the Bridge Notes, the Second Bridge Notes and the
Galenica Note.

    

    2.           Conversion.

    

    2.1           (a)           All
unpaid principal and unpaid accrued interest on this Note shall be automatically
converted into the Company’s equity securities (the “Securities”) issued
in the Company’s next equity financing (or series of related equity financings)
involving the sale of Securities in which the Company receives gross aggregate
cash proceeds (before brokers’ fees or other transaction related expenses, and
excluding any such proceeds resulting from any conversion of the Bridge Notes or
the Second Bridge Notes) of at least $10,000,000 minus the aggregate principal
amount of the Second Bridge Notes (a “Qualified
Financing”), at a conversion price equal to the lesser of (a) the lowest
per unit price paid for such Securities in cash by investors in such Qualified
Financing, and upon such other terms, conditions and agreements as may be
applicable in such Qualified Financing, and (b) $30,000,000 divided by the
number of shares of Common Stock outstanding immediately prior to such Qualified
Financing (determined on a fully diluted basis) (the “Conversion
Price”).

    

    (b)           In
the event that the Company consummates a merger, share exchange, or other
transaction (or series of related transactions), other than in connection with a
Qualified Financing, in which (i) the Company merges into or otherwise becomes a
wholly-owned subsidiary of a company subject to the public company reporting
requirements of the Securities Exchange Act of 1934, as amended, and (ii) the
aggregate consideration payable to the Company or its stockholders in such
transaction(s) (the “Reverse Merger
Consideration”) is greater than or equal to $10,000,000 (a “Reverse Merger”),
then immediately prior to such Reverse Merger, all unpaid principal and unpaid
accrued interest on this Note shall be automatically converted into Common Stock
at a conversion price per share equal to the quotient obtained by dividing (i)
the Reverse Merger Consideration less the amount of unpaid principal and accrued
interest on all Bridge Notes and Second Bridge Notes by (ii) the number of
shares of Common Stock then outstanding, on a fully diluted basis, without
giving effect to the warrants issued pursuant to the Purchase Agreements or to
the Placement Agent in connection with the sale of the Bridge Notes or to the
Second Bridge Warrants (as defined in the Purchase Agreement).

    

    The
shares of Common Stock issuable pursuant to clause 2.1(b) above shall be issued
effective prior to the consummation of the Reverse Merger and as a condition to
such Reverse Merger.  As a holder of such shares of Common Stock, the
Holder will receive the consideration payable in connection with such Reverse
Merger on a share-for-share basis with all other stockholders of the Company and
in like kind, at the same time and upon the same conditions as all other
stockholders of the Company.

    
      
         

      

      
        2

        
          

        

      

      
         

      

    

    

    If any
Reverse Merger Consideration is other than cash, its value will be deemed to be
its fair market value as determined, in good faith, by the Board of Directors of
the Company.  The value of any securities shall be determined by the
Board of Directors of the Company as set forth for a Sale of the Company in
Section 3.2(c) below.

    

    In the
event the Company completes (in one or a series of related transactions) a
merger, consolidation, sale or transfer of more than fifty percent (50%) of the
Company’s capital stock, in each case, which does not constitute a Sale of the
Company (as defined below), a Reverse Merger or a Qualified Financing, then the
term “Securities” as used
herein shall thereafter refer to the equity securities or securities convertible
into or exchangeable for equity securities of the surviving, resulting, combined
or acquiring entity in such merger, consolidation, sale or
transfer.

    

    2.2           Upon
conversion of this Note in accordance with the terms of Section 2.1, the
outstanding unpaid principal and unpaid accrued interest of the Note shall be
converted without any further action by the Holder and whether or not the Note
is surrendered to the Company or its transfer agent, and the indebtedness
evidenced by this Note shall be satisfied in full and no interest shall continue
to accrue on this Note and all rights of the Holder hereunder shall
terminate.  The Company shall not be obligated to issue certificates
evidencing the shares of the securities issuable upon such conversion unless the
Note is either delivered to the Company or its transfer agent, or the Holder
notifies the Company or its transfer agent that such Note has been lost, stolen
or destroyed and executes an agreement satisfactory to the Company to indemnify
the Company from any loss incurred by it in connection with such
Note.  The Company shall, as soon as practicable after such delivery,
or such agreement and indemnification, issue and deliver to such Holder of such
Note, a certificate or certificates for the securities to which the Holder shall
be entitled.  Such conversion shall be deemed to have been made
concurrently with the close of the Qualified Financing or the Reverse Merger, as
applicable.  The person or persons entitled to receive securities
issuable upon such conversion shall be treated for all purposes as the record
holder or holders of such securities on such date.  The Company shall
not issue fractional shares but shall round down the number of shares issued to
the nearest whole number.  Any conversion effected in accordance with
this Section 2 shall be binding upon the Holder hereof.

    

    3.           Prepayment.

    

    3.1           Other
than as provided in Section 3.2 hereof, the Notes may not be prepaid at any
time, in whole or in part, prior to their maturity.

    

    3.2           In
the event of a Sale of the Company prior to a Qualified Financing, the Company
shall:

    

    (a)           pay
to the Holder an amount equal to the unpaid principal balance of this Note,
payable in cash or such other form of Sale Proceeds (as defined below), having a
value equal to such unpaid principal balance;

    

    (b)           pay
to the Holder all accrued but unpaid interest on this Note, payable in cash or
such other form of Sale Proceeds, having a value equal to such accrued but
unpaid interest; and

    
      
         

      

      
        3

        
          

        

      

      
         

      

    

    

    (c)           as
consideration for the permitted prepayment of the Note, issue to the Holder a
number of fully paid, non-assessable shares of Common Stock equal to (i) the
Aggregate Prepayment Equity Amount (as defined below), multiplied by (ii) the
quotient equal to the principal amount of the Holder’s Note divided by the sum
of the aggregate principal amount of (w) all Bridge Notes plus (x) all Second
Bridge Notes plus (y) the Galenica Note plus (z) all Existing Notes (as defined
below), in each case, then outstanding.

    

    The
shares of Common Stock issuable pursuant to clause (c) above shall be issued
effective immediately prior to, and conditioned upon, the consummation of the
Sale of the Company and as a condition to such Sale of the
Company.  As a holder of such shares of Common Stock, the Holder will
receive the consideration payable in connection with such Sale of the Company on
a share-for-share basis with all other stockholders of the Company and in like
kind, at the same time and upon the same conditions as all other stockholders of
the Company.

    

    Upon the
consummation of the Sale of the Company and completion by the Company of the
deliveries set forth in clauses (a) through (c) above, the indebtedness
evidenced by this Note shall be satisfied in full and no interest shall continue
to accrue on this Note and all rights of the Holder hereunder shall
terminate.

     

    If any
Sale Proceeds resulting from the Sale of the Company are other than cash, the
value of such Sale Proceeds will be deemed to be its fair market value as
determined, in good faith, by the Board of Directors of the
Company.  The value of any securities shall be determined by the Board
of Directors of the Company as follows:

     

    (i)           Securities
not subject to an investment letter or other restriction on free marketability
covered by (ii) below:

     

    (A)           If
traded on a securities exchange, the value shall be the average of the daily
average bid and asked prices of the securities on such exchange over the thirty
(30) day period ending three (3) days prior to the date of the Sale of the
Company;

     

    (B)       
    If not traded on a securities exchange, but actively
traded over-the-counter, the value shall be the average of the daily average of
the closing bid and sale prices over the thirty (30) day period ending three (3)
days prior to the date of the Sale of the Company; and

     

    (C)         
  If not traded on a securities exchange and if there is no active
public market, the value shall be the fair market value thereof, as determined
by the Board of Directors with reference to the last sale of securities
undertaken by the issuer of such securities.

     

    (ii)           An
appropriate discount from the market value determined in accordance with clauses
(A), (B) or (C) of subsection (i) above shall be made with respect to any
securities subject to an investment letter or other restriction on free
marketability (other than restrictions arising solely by virtue of a
shareholder’s status as an affiliate or former affiliate) to reflect the
approximate fair market value thereof, as determined by the Board of
Directors.

    

    The
following definitions shall apply for purposes of this Section
3.2:

    
      
         

      

      
        4

        
          

        

      

      
         

      

    

    

    (v)           “Aggregate Prepayment Equity
Amount” shall mean a number of shares of Common Stock determined in
accordance with the following formula:

    

    
      
        	
                Aggregate
      Prepayment Equity Amount =    

              	
                 
      {

              	
                A

              	
                }

              	
                -
      A

              
	
                B

              

      

    

    

    For
purposes of the foregoing formula:

    

    A = the
number of shares of the Company’s then outstanding Common Stock, determined on a
fully diluted basis, prior to any issuance under this Section 3.2;

    

    B = the
Applicable Percentage (as defined below).

    

    (w)           “Applicable
Percentage” shall mean the number determined in accordance with the
following formula:

    

    
      
        	
                Applicable
      Percentage =   

              	
                1  -  
      

              	
                { 
      

              	
                ( A  x  B
    )

              	
                }

              
	
                C

              

      

    

    

    For
purposes of the foregoing formula:

    

    A = the
aggregate principal amount of all Bridge Notes, Second Bridge Notes, the
Galenica Note and Existing Notes outstanding immediately prior to the Sale of
the Company;

    

    B = 50%;
and

    

    C = the
aggregate principal amount of all Bridge Notes, Second Bridge Notes, the
Galenica Note and Existing Notes then outstanding.

    

    (x)           “Sale of the Company”
shall mean a transaction (or series of related transactions) with one or more
non-affiliates, pursuant to which such party or parties acquire (i) capital
stock of the Company or the surviving entity possessing the voting power to
elect a majority of the board of directors of the Company or the surviving
entity (whether by merger, consolidation, sale or transfer of the Company’s
capital stock or otherwise) (a “Stock Acquisition”);
or (ii) all or substantially all of the Company’s assets determined on a
consolidated basis (an “Asset Sale”); provided, however, that
notwithstanding anything to the contrary contained herein, to the extent any
transaction (or series of related transactions) qualifies as a Qualified
Financing or a Reverse Merger, such transaction(s) shall not be deemed to
constitute a Sale of the Company.

    

    (y)           “Sale Proceeds” shall
mean (i) in the event of a Stock Acquisition, the cash or securities paid by the
acquirer to the Company or the selling stockholders to acquire such shares; and
(ii) in the event of an Asset Sale, the cash or securities legally available for
distribution to the Company’s stockholders, after creation of adequate reserves
for liabilities of the Company.

    
      
         

      

      
        5

        
          

        

      

      
         

      

    

    

    (z)           “Existing Notes” shall
mean (i) the Future Advance Promissory Note in favor of Paramount BioSciences,
LLC, dated July 28, 2006 and amended on June 15, 2007, (ii) the Future Advance
Promissory Note in favor of The Lindsay A. Rosenwald Family Trusts Dated
December 15, 2000, dated August 11, 2006 and amended on June 15, 2007 and on
July 22, 2008, and (iii) such additional amounts, if any, borrowed under one or
more of the foregoing notes to fund the operations of the Company.

    

    4.           Attorney’s
Fees.  If the indebtedness represented by this Note or any part
thereof is collected in bankruptcy, receivership or other judicial proceedings
or if this Note is placed in the hands of attorneys for collection after
default, the Company agrees to pay, in addition to the principal and interest
payable hereunder, reasonable attorneys’ fees and costs incurred by
Holder.

    

    5.           Notices.  Any
notice, other communication or payment required or permitted hereunder shall be
in writing and shall be deemed to have been given upon delivery to the address
provided pursuant to the Purchase Agreement.  In the case of notice to
either party, copies should be sent to Olshan Grundman Frome Rosenzweig &
Wolosky LLP, Park Avenue Tower, 65 East 55th Street, New York, NY 10022,
Facsimile: (212) 451-2222, Attn: Yehuda Markovits, Esq.

    

    6.           Notice of Proposed
Transfers.  Prior to any proposed transfer of this Note or the
Securities, unless there is in effect a registration statement under the
Securities Act covering the proposed transfer, the Holder shall give written
notice to the Company of such Holder’s intention to effect such
transfer.  Each such notice shall describe the manner and
circumstances of the proposed transfer in sufficient detail, and shall, if the
Company so requests, be accompanied (except in transactions in compliance with
Rule 144) by an unqualified written opinion of legal counsel, who shall be
reasonably satisfactory to the Company, addressed to the Company and reasonably
satisfactory in form and substance to the Company’s counsel, to the effect that
the proposed transfer of the Note or Securities may be effected without
registration under the Securities Act; provided, however, no such
opinion of counsel shall be necessary for a transfer without consideration by a
Holder to any affiliate of such Holder, or a transfer by a Holder which is a
partnership to a partner of such partnership or a retired partner of such
partnership who retires after the date hereof, or to the estate of any such
partner or retired partner or the transfer by gift, will or intestate succession
of any partner to his spouse or lineal descendants or ancestors, if the
transferee agrees in writing to be subject to the terms hereof to the same
extent as if such transferee were the original Holder hereunder.  Each
certificate evidencing Securities or the Note transferred as above provided
shall bear an appropriate restrictive legend, except that the Note or
certificate shall not bear such restrictive legend if in the opinion of counsel
for the Company such legend is not required in order to establish compliance
with any provisions of the Securities Act.

    

    7.           Acceleration.  This
Note shall become immediately due and payable if (i) the Company commences any
proceeding in bankruptcy or for dissolution, liquidation, winding-up,
composition or other relief under state or federal bankruptcy laws; or (ii)
there is any material breach of any material covenant, warranty, representation
or other term or condition of this Note or the Purchase Agreement at any time
which is not cured within the time periods permitted therein, or if no cure
period is provided therein, within sixty (60) days after the date on which the
Company receives written notice of such breach.

    

    8.           No Dilution or
Impairment.  The Company will not, by amendment of its
Certificate of Incorporation or Bylaws or through any reorganization, transfer
of assets, consolidation, merger, dissolution, issue or sale of securities or
any other voluntary action, avoid or seek to avoid the observance or performance
of any of the terms of this Note, but will at all times in good faith assist in
the carrying out of all such terms and in the taking of all such action as may
be necessary or appropriate in order to protect the rights of the Holder of this
Note against dilution or other impairment.

    
      
         

      

      
        6

        
          

        

      

      
         

      

    

    

    9.           Waivers.  The
Company hereby waives presentment, demand for performance, notice of
non-performance, protest, notice of protest and notice of
dishonor.  No delay on the part of Holder in exercising any right
hereunder shall operate as a waiver of such right or any other right. This Note
is being delivered in and shall be construed in accordance with the laws of the
State of New York, without regard to the conflicts of laws provisions
thereof.

    

    10.           No Stockholder
Rights.  Nothing contained in this Note shall be construed as
conferring upon the Holder or any other person the right to vote or to consent
or to receive notice as a stockholder of the Company.

    

    11.           Amendment.  Any
term of this Note may be amended with the written consent of the Company and the
holders of not less than sixty-six and two-thirds percent (66 2⁄3%) of the then
outstanding aggregate principal amount of the Bridge Notes, the Second Bridge
Notes and the Galenica Note, consenting together as one group, even without the
consent of the Holder hereof.  Any amendment effected in accordance
with this Section 11 shall be binding upon each holder of any Bridge Note, each
holder of any Second Bridge Note, the holder of the Galenica Note, each future
holder of all such Bridge Notes, Second Bridge Notes or the Galenica Note, and
the Company; provided, however, that no special consideration or inducement may
be given to any such Holder in connection with such consent that is not given
ratably to all such holders, and that such amendment must apply to all such
holders ratably in accordance with the principal amount of their then
outstanding Bridge Notes, Second Bridge Notes or the Galenica
Note.  Pursuant to Section 2.17 of the Purchase Agreements and Section
1 of the Bridge Notes, the Second Bridge Notes and the Galenica Note, the
Company may incur additional indebtedness that ranks in priority junior to, or
pari passu with, the Bridge Notes, the Second Bridge Notes and the Galenica Note
without obtaining the consent of any holder of Bridge Notes, Second Bridge Notes
or the Galenica Note.  The Company shall promptly give notice to all
holders of outstanding Bridge Notes of any amendment effected in accordance with
this Section 11.

    

    *  *  *  *  *

     

    
      
        
        

      

      
        7

        
          

        

      

      
        
        

      

    

     

    ISSUED as
of the date first above written.

    

    
      
        
          	 
      	
                  CORMEDIX
      INC.

                
	 
      	 
      	 
      
	 
      	
                  By:

                	
                     

                
	 
      	
                  Name:

                	
                  Bruce
      Cooper, M.D.

                
	 
      	
                  Title:

                	
                  President
      and Chief Executive
Officer

                

        

      

    

     

    
      
         

      

      
        8

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00165-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00165-of-00352.parquet"}]]